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enjoyed teaching medical students the significance of epidemiology and statistics. An 
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me feel included, even though my visits were rare. This was due to the fact that my work 
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In human biomonitoring (HBM) of exposure, concentrations of xenobiotic compounds are 
measured in biological tissues. We have investigated two groups of emerging contaminants 
with different source of exposure namely, perfluoroalkyl subtances (PFASs) and cyclic 
volatile methylsiloxanes (cVMS). PFASs are ubiquitous in the environment world-wide, and 
cVMS are present as constituents in many personal care products (PCPs). The primary 
exposure route for PFASs is the diet, whereas dermal application of PCPs is so for cVMS. In 
terms of persistence, the human half-life for PFASs is several years, while for cVMS it is two 
to three days.  
Our primary objective for PFASs was to assess exposure in blood in delivering women and 
their new-born residing in countries for which this information was lacking, specifically: 
South Africa, the industrial city of Norilsk (arctic Russia) and the rural Aral Sea region of 
Uzbekistan. A secondary objective was to evaluate the distribution of PFASs between blood 
cell and plasma fractions. In terms of cVMS, we wanted to evaluate if they were present in 
blood plasma of pregnant and postmenopausal Norwegian women, and to investigate 
possible links to self-reported use of PCPs for the latter group. 
The PFAS concentrations in delivering women were highest in arctic Russia followed by 
South Africa and Uzbekistan. Put in context with other studies, year of sampling and 
geographical location were main predictors for PFASs exposure. Even though plasma and 
serum are the biological tissue most often used in HBM studies, we observed that whole 
blood contained considerably amount of a perfluorooctane sulfonic acid (PFOS) precursor, 
namely perfluorooctane sulfonamide (FOSA). Compared to PFOS and other “ionic” PFASs, 
reporting FOSA concentrations in plasma (or serum) results in an underestimation of 
exposure. Specifically, the concentration in whole blood was up to six times higher than in 
plasma. The rather basic pKa value of FOSA appears to explain this difference in distribution.  
The majority of the women had paired umbilical cord samples, and the presence of PFASs 
in these samples showed that the unborn child is also exposed to these compounds. When 
comparing concentrations of compounds with the same number of backbone carbons in 
maternal and cord plasma and whole blood, the data suggest that a perfluoroalkyl 
carboxylic acid (PFCA) passes the placenta more easily than the corresponding 
perfluoroalkyl sulfonic acid (PFSA).  
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The ubiquitous presence of cVMS in the general environment make their analysis 
challenging. Several novel actions were implemented to minimize inadvertent 
contamination. The plasma cVMS concentrations reported are the first for women from the 
general population. Information about PCP used was not significant correlated with cVMS 
concentration. It should be pointed out that even though the majority of the investigated 
cVMS were present below the detection limit, the concentrations that were found were still 
substantial compared to those for prominent persistent organic pollutants (POPs). For 
example, the Limit of quantification (LOQs) for the cVMS were three times the currently 
reported concentration of PCB 153, a compound we still are concerned about. The cVMS 
add to the mixture of xenobiotic compounds in human blood and thus contribute to the 





Mennesker eksponeres for en rekke miljøgifter gjennom diett og ved bruk av produkter som 
er ment til å forbedre hverdagen. I human overvåkning (HBM) kartlegges mengden 
fremmedstoffer i kroppen.  
Vi har undersøkt to grupper fremmedstoffer som betegnes som nye; perfluoralkyl 
forbindelser (PFASs) og sykliske siloksaner (cVMS). Kildene til den humane eksponeringen 
for disse forbindelsene er ulike. PFASs er utbredt i miljøet over hele verden, og cVMS er 
tilstede, i varierende mengder, i mange typer hudpleie produkter. For PFASs er 
hovedeksponeringen via mat mens for cVMS er påføring/bruk av hudpleie produkter en 
kilde. Disse to gruppene av fremmedstoffer har ulik persistens (levetid i miljøet og 
mennesket) der den humane halveringstiden for PFASs flere år, mens for siloksaner er den 
under en uke. 
Vårt primære mål var å undersøke eksponeringen til disse stoffene, det vil si mengden PFASs 
i blodet til fødende kvinner og deres nyfødte barn (navlestrengsblod) bosatt i land der 
denne informasjonen var mangelfull; Sør Afrika, Norilsk (industriby i arktiske strøk av 
Russland) og landsbygda nær Aral sjøen i Usbekistan. Et sekundært mål var å se på 
fordelingen av PFASs mellom blodcellene og plasma i mor og navlestrengsblod. For cVMS 
ønsket vi å se om de var tilstede i blodet til gravide og postmenopausale kvinner fra Norge, 
og videre undersøke om det var en sammenheng mellom konsentrasjonene og bruk av 
hudpleieprodukter i den siste gruppen.  
PFAS konsentrasjonen i de fødende kvinnene var høyest i arktiske strøk av Russland 
etterfulgt av Sør Afrika og Usbekistan. Konsentrasjonene var generelt lavere enn i den 
vestlige verden. Sammenligning med andre studier viste at innsamlingsår og geografisk 
lokalisering var hovedprediktorer for den målte PFASs konsentrasjonen. Selv om plasma og 
serum er de biologiske væskene oftest brukt i HBM studier, observerte vi at fullblod 
inneholdt betydelige mengder av en forløper til perfluoroktansulfonat (PFOS), 
perfluoroktansulfonamid (FOSA). Sammenlignet med PFOS og andre «ioniske» PFASs, har 
eksponeringen til FOSA i tidligere studier vært underestimert når plasma/serum har vært 
undersøkt. Konsentrasjonen av FOSA i fullblod var opptil seks ganger høyere sammenlignet 
med plasma. Den høye pKa verdien for FOSA, hvor FOSA ikke er fullstendig dissosiert ved 
fysiologisk pH, sammenlignet med andre PFASs kan forklare denne forskjellen i distribusjon.   
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For majoriteten av kvinner hadde vi navlestrengsblod tilgjengelig, og tilstedeværelsen av 
PFASs i disse prøvene viser at det ufødte barnet er eksponert for disse forbindelsene. Ved 
sammenligning av konsentrasjonene til forbindelser med lik kjedelengde av den fluorerte 
karbonkjeden, fant vi at perfluoralkylkarboksylater (PFCA) passerer placenta lettere enn den 
korresponderende perfluoralkylsulfonaten (PFSA).  
Der hvor mennesker oppholder seg er det også cVMS er tilstede, og analysen av disse 
forbindelsene er derfor utfordrende. Flere tiltak ble gjennomført slik at kontaminering fra 
mulige kilder ble minimert. For første gang er cVMS rapportert i plasmaprøver fra en 
populasjonsbasert kohorte. Mengden cVMS varierte fra ikke detektert til 12.7 ng/mL. 
Informasjon om PCP bruk var ikke signifikant korrelert med målt cVMS konsentrasjon. Det 
må bemerkes at selv om majoriteten av de undersøkte cVMSene var under 
deteksjonsgrensen, var konsentrasjonen betydelig sammenlignet med de kjente 
miljøgiftene slik som polyklorerte bifenyler (PCB). For eksempel er kvantifiseringsgrensen 
(LOQ) for cVMS tre ganger høyere enn konsentrasjoner nylig rapportert for PCB 153, en 
forbindelse man fortsatt er bekymret for. cVMS kan legges til den allerede kjente listen av 
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The general population is exposed daily to a wide range of anthropogenic compounds 
through the diet and the handling of consumer products meant to improve everyday life. 
Several of them have been shown to have adverse effects both in the environment and in 
humans. The legacy POPs (persistent organic pollutants), such as organochlorine pesticides 
and polychlorinated biphenyls (PCBs) (see Figure 1 for structural details) have been of 
special interest. They biomagnify, are persistent in the environment (long half-lives) and 
undergo long range transport (LRT) (AMAP, 2003; 2004a). International agreements, such as 
the Stockholm Convention on POPs, have resulted in restricted production and use. As a 
result, the concentration of these compounds has decreased over time in the environment 
and so has the exposure of the general human population. More recently, other organic 
contaminants are being identified as being widely distributed. Examples are brominated 
flame retardants (BFRs), perfluoroalkyl and polyfluoroalkyl substances (PFASs) and silicones 
(see Figure 1). They are designated as emerging contaminants even though they have been 
commercially available, since the beginning of the 1970s, 1950s and 1940s (Prevedouros et 
al., 2004; Paul et al., 2009; Wang et al., 2012), respectively. At the beginning of the 21st 
century, improved analytical equipment and techniques confirmed the presence of PFASs 
in human serum and the general environment world-wide (Giesy and Kannan, 2001; Hansen 
et al., 2001). To circumvent similar delayed environmental contamination legacies, model-
based tools are used today. The silicones (more specifically cyclic volatile methylsiloxanes; 
cVMS) constitute a concern because of their predicted persistence, bioaccumulative 
characteristics and high production volume (Howard and Muir, 2010; Warner et al., 2010; 
Kierkegaard et al., 2011).  
The research described in this thesis focuses on human biomonitoring (HBM) aspects of 






1.2 PRODUCTION AND USE 
1.2.1 Perfluoroalkyla and polyfluoroalkylb substances (PFASs)  
PFASs have been produced since 1949 and, as mentioned, were commercially available 
shortly thereafter (Prevedouros et al., 2006; Paul et al., 2009). As illustrated in Figure 1, a PFAS 
consists of a hydrophobic fully fluorinated alkyl chain and a hydrophilic functional group. 
These chemical/structural features confer PFASs unique properties including: being 
“chemically inert, non-wetting, very slippery, non-stick, highly fire resistant, very high-
temperature ratings, and highly weather resistant”, and initially they were considered as 
nontoxic (Herzke et al., 2012). The major commercial uses of PFASs has been as raw materials 
for surfactant and surface protection products, but also as components of: inks, varnishes, 
waxes, fire fighting foams, metal plating and cleanings, coating formulations, lubricants, 
water and oil repellents for leather, paper and textiles, and insecticide (Butenhoff et al., 2006; 











aPerfluoroalkyl compounds: All of the hydrogen in the alkyl chain have been substituted 
with fluorine (e.g., Perfluorooctanoic acid; PFOA). 
bPolyfluoroalkyl compounds: Some of the hydrogen in the alkyl chain have been 




p,p-DDE (a legacy POP) 
 
PCB 153 (a legacy POP) 
 
PBDE 47 (a BFR) 
 
PFOS (a PFAS) 
 
D5 (a cVMS) 
 
Figure 1. Chemical structures of p,p-DDE (p,p-dichlorodiphenyl dichloroethene), PCB 153, 
PBDE (polybrominated diphenyl ether) 47, PFOS (perfluorooctane sulfonic acid) and D5 




Two main production processes have been employed in the production of PFASs, namely 
electrochemical fluorination (ECF) and telomerisation (see Figure 2). Until 2002, the 3M 
Company (3M) was the major global manufacturer of perfluorooctane sulfonyl fluoride 
(POSF) using the ECF production method (see Figure 3) (Paul et al., 2009). During this 
process, an impure mixture of linear and branched isomers and chain-length homologs are 
formed (Lau et al., 2007; Benskin et al., 2009a). POSF and salts of perfluorooctanoic acid 
(PFOA) were the main products. POSF served as a building block in the synthesis of high 
molecular weight fluorochemical products, and the ammonium salt of PFOA in the 
manufacture of fluoropolymers (Buck et al., 2011). POSF-based derivatives served as major 
raw materials for surfactants and surface protection products and included the following 
neutral volatile compounds: N-methyl perfluorooctane sulfonamidoethanol (MeFOSE), N-
ethyl perfluorooctane sulfonamidoethanol (EtFOSE), N-Methyl perfluorooctane 
sulfonamide (MeFOSA), and N-Ethyl perfluorooctane sulfonamide (EtFOSA) (Buck et al., 
2011). Perfluorooctane sulfonic acid (PFOS) was produced in minor quantities (Paul et al., 
2009). In total, 96 000 tonnes of POSF were produced (Paul et al., 2009). The estimated global 
POSF production volume from 1970-2002 is presented in Figure 3. 
Perfluoroalkyl carboxylic acids (PFCAs), fluorotelomer alcohols (FTOHs), fluorotelomer 
iodides and fluorotelomer olefins were among the products of the telomerisation process, 
which have been used by various companies since the 1970s (Butt et al., 2010). These 
compounds were used as building blocks in the synthesis of polyfluorinated polymers for 
use as ingredients of textile treatment surfactants, and grease-proof food contact paper 
(Buck et al., 2011; Lindstrom et al., 2011). Unlike the ECF process, telomerisation leads to a 
homologous series of linear perfluoroalkyl chains with even-numbered carbon chain-












Figure 2. Simplified description of the ECF (A) and telomerization (B) processes (adapted 





Figure 3. Estimated global POSF production volume (1970-2002), purple line; 3M’s 
production, orange line (adapted from Paul et al., 2009). 
 
1.2.2 Cyclic volatile methylsiloxanes (cVMS) 
Siloxanes (also known as organosiloxanes; Brooke et al., 2009a-c) are widely used chemicals 
and constitute the building blocks of silicone products. Silicones exhibit high thermo 
stability, chemical resistance, inertness and good lubrication properties, and have been used 
as an alternative to PCBs (Dow Corning, 2004). While the stability of silicones are desirable 
from a technical point of view, it renders them environmentally persistent. Silicones on 
treated polymers serve as an alternative to fluorinated chemicals since they offer good water 
repellency (Posner, 2012), and are used in a number of industrial applications and consumer 
products (Kaj et al., 2005a; Horii and Kannan, 2008; Wang et al., 2009).  
Productions of silicones are carried out primarily in the USA, Germany, Japan, France and 
the U.K. (Lassen et al., 2005). However, China has become the largest manufacturer and 
consumer of polysiloxanes in the world (Wang et al., 2012). Globally the use of silicones sums 
to 850 000 tonnes (Lassen et al., 2005). The production volume estimates for 2006 covered 
quite a range: 45 000 - 227 000 tonnes (octamethylcyclotetrasiloxane; D4) and 23 000 – 
45 000 tonnes (decamethylcyclopentasiloxane; D5) (Howard and Muir, 2010). Recent 
numbers from China indicate that the output of polysiloxanes for 2008 and 2009 was 
195 000 and 270 000 tons, respectively (Wang et al., 2012). According to the database on the 








































































































Registries of Norway, Sweden, Denmark and Finland), the registered use of D4, D5 and D6 
(dodecamethylcyclohexasiloxane) in substances, and have in Norway have decreased since 
2004 (see Figure 4). However, the declaration of cVMS in personal care products (PCPs) is not 
mandatory in Norway (Huse and Aas-Aune, 2009), and therefore not included in this figure.  
There are five major groups of organosiloxanes: oligomeric organosiloxanes (also known as 
the volatile methyl siloxanes); polymeric dimethylsiloxanes, modified polymeric 
dimethylsiloxanes, organosiloxane resins and organosiloxane elastomers. Of the latter four 
categories (organosiloxane resins exempted), all could contain traces of cVMS, specifically: 
D4, D5 (see Figure 1 for chemical structure) and D6. Oligomeric organosiloxanes (especially 
D4 and D5) are used in PCPs, specifically as carriers in antiperspirants, deodorants, skin care 
products, and as conditioners in hair care products. To enhance skin smoothness and 
softness when using PCPs, siloxanes are added to cosmetic lotions as emollients 
(moisturizers) (Brooke et al., 2009a-c). Other properties, such as the high volatility of cVMS, 
are desirable since most of that applied evaporates from the skin within 24 h (Reddy et al., 
2007). In addition to PCPs, siloxanes are used in a number of industrial applications and in 
consumer products including: fuels, car polishes, cleaners, anti-foaming agents, and car 
waxes (Lassen et al, 2005).  
The numerous applications of cVMS, and especially their high volatility, have raised concern 
about these compounds within environmental science disciplines (Kaj et al., 2005a). D5 is 
currently being subjected to regulatory scrutiny, including the suggestion that it should be 




Figure 4. Tonnes of cVMS in Norway registered used in the SPIN database (SPIN, 2012).  
 
 
1.3 SOURCES AND ENVIRONMENTAL DISTRIBUTION 
1.3.1 PFASs  
PFASs were perceived to be biologically inert primarily because of their incorporation into 
polymers (Giesy and Kannan, 2001). On this basis, they were believed to have little impact 
on the environment, including human health.  
They are known to be released into air, water and land during their manufacture and via 
secondary products such as fire fighting foams and their presence in consumer products. 
They have been detected in a variety of environmental matrices such as air, surface water, 
sludge, soil, sediments, and ice caps (Lau et al., 2007). The highest environmental 
concentrations have been reported for the northern hemisphere (Jahnke et al., 2007; Ahrens 
et al., 2009), where the majority of the PFAS production has taken place (OECD, 2002). 
However, there has been some limited production in Brazil (Danish EPA, 2005). 
Concentrations in various air and water indicate limited mass exchange of PFASs between 
the two hemispheres (Jurado et al., 2004).  
The relatively long half-life in air of 10-20 days and ability to undergo LRT of the precursors 
to PFOS and PFOA, namely FOSEs, FOSAs and FTOHs, potentially permits transport to 




























degradation (biotransformation), PFOS and PFOA are the major end products. The latter are 
stable compounds with no known natural degradation pathways (Ellis et al., 2004; Plumlee 
et al., 2009; Martin et al., 2010; Buck et al., 2011; Lindstrom et al., 2011). Another transport 
pathway is by water, which would be more relevant for the ionic compounds of PFCA and 
perfluoroalkyl sulfonic acids (PFSAs).  
Long chain PFSAs and PFCAs with eight carbon atoms or more in the fluorinated chain 
accumulate significantly in the food chain (Conder et al., 2008). This implies that PFOS (8 
carbons) bioaccumulates and PFOA (7 carbons) has a lower potential to do so (Butt et al., 
2010); nevertheless, both compounds are environmentally persistent. In 2009 PFOS was 
included in Annex B of the Stockholm Convention, which restricts its use and production 
(UNEP, 2011).  
 
1.3.2 cVMS  
Release from industrial processes related to the production and use of silicone polymers and 
disposal of PCPs are the primary environmental sources of cVMS (Environment Canada and 
Health Canada, 2008 a-c). More than 90% are released to the atmosphere and the remainder 
is discharged to waste water (Genualdi et al., 2011). cVMS are eliminated from the 
atmosphere largely by reactions with OH to form silanols, which are scavenged by wet 
deposition. Neither wet nor dry depositions of the native cVMS are expected (McLachlan et 
al., 2010). The half-lives in the atmosphere of D4 and D5 are approximately 15 and 10 days 
respectively, and are sufficiently long to undergo LRT to remote regions such as the Arctic 
(McLachlan et al., 2010). 
cVMS have been detected in matrices including air, water, sediments, fish and birds, even in 
the Arctic (Sparham et al., 2008; Evenset et al., 2009; McLachlan et al., 2010; Warner et al., 
2010; Sparham et al., 2011). The highest concentrations in water and sediments are found 
close to effluent sources. Air samples are dominated by D5 and D6 near cities, whereas in D3 
and D4 dominate in remote locations (Genualdi et al., 2011). Surface water concentrations 
of cVMS reflect their divergent solubilities in this medium. In other environmental samples, 
concentrations of D5 have often exceeded those of D4 and D6 (Warner et al., 2010). This 
mirrors the larger production of D5 (in Europe) compared to D4 (Wang et al., 2012). 
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On release, the residence time in air of D5 is 2.9 days and, based on model simulations, is 
considerably longer in water (estimated at 201 days; Hughes et al., 2012). The latter implies 
distribution to the water column and sediments. A more realistic scenario with respective 
releases of 94.5%, 0.8% and 4.7% D5 into air, water and soil, respectively, gave and overall 
residence time in the environment of 4.6 days. A trophic magnification factor (TMF) 
significantly greater than one has been reported for D5 (Borgå et al., 2012), suggesting food 




1.4 HUMAN BIOMONITORING OF EXPOSURE 
1.4.1 Preamble  
“Human biomonitoring (HBM) involves the monitoring of dose, effect and susceptibility in body 
fluids or tissues (Nieboer et al., 1999; WHO, 1993). A biomarker of exposure is “the 
environmental contaminant, its metabolite, or a product resulting from its interaction with the 
target tissue”; a biomarker of effect corresponds to “a measurable biochemical, physiological 
behavioural or other alteration within an organism that, depending upon the magnitude, can 
be recognized as associated with an established or possible health impairment or disease”; and 
a biomarker of susceptibility is “an indicator of an inherent or acquired ability of an organism 
to respond to the challenge of exposure to a specific xenobiotic substance” (WHO, 1993). 
Exposure biomarkers are assessed through measuring the presence and concentration of 
chemicals in blood, urine, hair, nails or breath (exhaled air)” (Odland and Nieboer, 2012). Of 
course other tissues can also be used, such as breast milk meconium, saliva, sweat, and 
semen (Esteban and Castano, 2009). Clearly, the work described in this thesis is limited to 
biomarkers of exposure in body fluids, namely plasma, serum and whole blood. 
Specimens collected from pregnant and delivering women, namely blood (whole blood, 
serum, or plasma) and breast milk, have been used as biomarkers of fetal and/or neonatal 
exposure. The ability to cross the placenta varies, with the majority of contaminants doing 
so and thereby entering the fetal circulation. Another common way of assessing fetal 
exposure involves analysing cord blood at birth. Amniotic fluid and meconium also have 
received attention for this purpose (Barr et al., 2005; Jensen et al., 2012). The half-life of 
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xenobiotics in meconium may be protracted, and thus measured concentration of 
contaminants may reflect cumulative exposure from the second trimester to delivery 
(Whyatt et al., 2009).  
 
1.4.2 PFASs  
Since 2001 there have been several reports on PFAS concentrations in the general 
population. Whole blood, serum and plasma have been used as sample matrices to 
determine the internal exposure. However the majority of the studies have reported PFAS 
concentrations for the latter two (Lau et al., 2007; Martin et al., 2010). A likely reason is that 
they are preferred matrixes from the analytical perspective, are routinely used in clinical 
chemistry (Burtis et al., 2006), and have often been collected for storage in bio-banks. The 
PFAS concentrations in plasma and serum have shown to be comparable, although there 
have been some uncertainties when whole blood concentrations have been compared with 
plasma and serum concentrations. It has generally been assumed that concentrations in 
serum and plasma measurements would be approximately twice that in whole blood 
because of its cellular components (Kannan et al., 2004; Kärrman et al., 2006). This has shown 
to be valid for ionic PFASs such as PFOS and PFOA (Ehresman et al., 2007), although the 
plasma-to-whole blood ratio for FOSA has been reported to be 0.2 (Kärrman et al., 2006). In 
contrast to POPs, only minor amounts of PFASs appear stored in the lipids (Jones et al., 2003). 
The question of the proper media for PFAS measurements remains unresolved. In recent 
animal studies, whole blood has been the preferred sample matrix to determine the internal 
exposure to some PFASs (D’eon and Mabury, 2010; Ross et al., 2012). 
Exposure to contaminants usually decreases in the order: occupational exposure > 
populations with identified local exposure sources (including LRT) > the general population 
(i.e., background exposure). Biomonitoring studies of workers involved in the production of 
PFAS, or the manufacture of products containing them, have shown serum concentrations 
exceeding 10 000 μg/L (PFOS) and > 100 000 μg/L (PFOA) (Fromme et al., 2009). Recently, 
elevated exposure to PFASs among ski waxing technicians has been reported (Nilsson et 
al., 2010). Among populations with identified local exposure sources (e.g., in Sauerland, 
North Rhine-Westphalia, Germany and Little Hocking, Ohio, USA), PFASs have been 
detected in the municipal drinking water, with PFOA the most prominent compound found 
(Fromme et al., 2009; Steenland et al., 2009). LTR appears to contribute to PFAS exposures 
of indigenous peoples living at northern latitudes (local food is a source) (Ostertag et al., 
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2009; Donaldson et al., 2010). In the general population, diet has been considered the major 
exposure pathway for PFASs (including food packaging materials) (Fromme et al., 2009; 
Domingo, 2012). By analogy to brominated compounds (e.g., PBDEs), house dust may well 
constitute an exposure source. PBDEs are ubiquitous in household products (including 
common food items, upholstery, textiles, building materials, kitchen appliances, plastic 
products and electronics). This exposure pathway has been shown to be significant, 
especially for toddlers who ingest more dust than adults (Frederiksen et al., 2009; 2010). 
Indeed, house dust also appears to contribute to PFASs exposure (Domingo, 2012) for which 
the concentrations of PFAS precursors are often higher than the ionic PFASs (Haug et al., 
2011). 
The measurement of contaminants in exposure media such as air, house dust, drinking 
water and foods allows intake doses to be calculated. Which of these exposure sources 
dominates depends on the type of compound and the uptake route. Several studies have 
analysed food baskets (Ericson et al., 2008; Kärrman et al., 2009; Haug et al., 2010; Vestergren 
et al., 2012), or employed food consumption questionnaires (Halldorsson et al., 2008; 
Rylander et al., 2010) to link diet with plasma or serum concentrations. The results are not 
consistent, which suggests multiple sources and ubiquitous distribution of these 
compounds. Study cohort characteristics (e.g., age, gender, socioeconomic factors and life-
style issues, and the year of sampling) likely have influenced the results. Until recently, PFOS 
was thought to be fairly uniformly distributed in food items. However, dietary items 
consumed by indigenous populations in Arctic regions, such as fish and marine mammals, 
appear to be major predictors of exposure by analogy to the legacy POPs (Dallaire et al., 
2009; Ostertag et al., 2009).  
The PFAS concentrations in whole blood, plasma or serum have varied. The highest 
concentrations have been observed in populations of industrialized northern hemisphere 
countries (Kannan et al., 2004), although PFAS concentrations for Australian adults have 
shown to be of comparable magnitude (Kärrman et al., 2007a). The ability for PFASs to cross 
the placenta have been shown in several studies (e.g., Inoue et al, 2004; Midasch et al., 2006; 
Fei et al., 2007; Monroy et al., 2008). In general, the concentrations reported have been the 
half of the maternal concentration. After delivery, the new-born child continues to be 
exposed to PFASs through breast milk. Even though PFOS concentrations in breast milk are 
typically 1% of the corresponding maternal serum concentration, corresponding value for 
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PFOA is 12% (Kärrman et al., 2007b), the amount milk consumed still makes this exposure 
pathway significant. 
After the phase-out of the ECF production (see Figure 3), PFAS concentrations in the general 
population have decreased. Analysis of pooled serum samples from Norwegian men 
collected from 1976 to 2007 revealed declining concentrations of perfluorohexane sulfonic 
acid (PFHxS), PFOS and PFOA, but not for longer chain PFCAs (Haug et al., 2009). A similar 
trend was observed for serum samples from Red Cross blood donors in the U.S sampled in 
the period 2000-2010 (Olsen et al., 2012). However, the continued PFOS production in China 
(Butt et al., 2010) might affect time trends for other geographical areas.  
 
1.4.3 cVMS  
Compared to PFASs, POPs and other environmental contaminants, fewer HBM studies have 
focused on cVMS. In a recently published study, siloxane concentrations in plasma from a 
population working and living near a siloxane production facility was reported (Xu et al., 
2012). Other published reports on cVMS in humans have investigated amounts in adipose 
tissue (US EPA, 1987), whole blood and plasma collected from women with silicone breast 
implants (Flassbeck et al., 2001). Flassbeck et al. (2003) also reported cVMS in fat and muscle 
tissues from women with breast implants. One or more of D4, D5 and D6 have been found 
in 11 out of 49 samples of human breast milk in an environmental siloxane survey by the 
Swedish EPA (Kaj et al., 2005b). The need for more knowledge about cVMS exposure from 
PCPs has recently been highlighted by several authors (Horii and Kannan, 2008; Wang et al., 
2009).  
Environmental human exposure to cVMS is not considered to be of great concern (Brooke 
et al., 2009a-c). However, it is evident from the studies by Horii and Kannan (2008) and Wang 
et al. (2009a) that humans by usage of cosmetics and PCPs can become exposed because of 
the high concentrations of cVMS in some of these products. The content of cVMS in PCPs 
varies widely, from a few percent to more than 90 percent (Brooke et al., 2009a). The content 
and composition of cVMS in a wide range of PCPs have been reported for Canada, United 
States, Japan and China (Horii and Kannan, 2008; Wang et al., 2009; Lu et al., 2011); D5 was 
the dominant siloxane in PCPs, except in China where linear siloxanes were most prevalent). 
Based on daily PCPs usage and mean concentrations, the daily exposure to total siloxanes 
(linear and cyclic) was estimated to 307 mg/day for women in the United States (Horii and 
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Kannan, 2008). The corresponding values for Canadian and Chinese women were 996 
mg/day and 4.51 mg/day, respectively (Wang et al., 2009; Lu et al., 2011). The high volatility 
of cVMS implies that air is a potential exposure pathway, although the primary route for 
humans can be presumed to be dermal absorption following application of PCPs. Of course, 
exposure through inhalation would be pertinent in occupational settings (Cornelis, 2005). 
The concentrations of cVMS in dust appear to be low, with a calculated daily exposure to 
total siloxanes from this source of 15.9 ng/day in China (Lu et al., 2010).  
 
 
1.5 HEALTH EFFECTS 
1.5.1 PFASs 
Due to the widespread distribution and persistence of these compounds, several research 
groups have elucidated their toxicity and toxicokinetics. Since PFOS and PFOA are the most 
common PFAS in biological matrices, the majority of such studies have investigated these 
end products.  
PFAS are readily absorbed in the gastrointestinal tract (Lau et al., 2004). They are distributed 
into the extracellular volume (Noker and Gorman, 2003; Butenhoff et al., 2004), and is also 
found in liver, kidney and blood (Lau et al., 2007). Ionic PFAS are associated with β-
lipoproteins, liver fatty-acid binding proteins and albumin (Luebker et al., 2002; Han et al., 
2003; Jones et al., 2003). They are not known to be metabolised, and are excreted by way of 
urine and bile. Elimination rates differ considerable between species, and for some species 
also between sexes (Lau et al., 2007). Humans eliminate PFASs very slowly compared to 
other species and could be explained by renal reabsorption and enterohepatic circulation 
(Harada et al., 2005; 2007). In retired fluorochemical production workers, the geometric 
means of half-lives were: 4.8 y (PFOS), 3.5 y (PFOA), and 7.3 y (PFHxS) (Olsen et al., 2007a). 
The half-lives of PFOA and PFOS have recently been confirmed to be within the same range 
(Seals et al., 2011; Olsen et al., 2012).  
The liver is considered to be the primary target organ with respect to exposures from PFOS 
and PFOA (Cui et al., 2010). Repeat-dose studies of both compounds in rodents have 
reported reduced body weight, increased liver weight, and reduced cholesterol levels (Lau 
  28
et al., 2007). Other toxicological findings in addition to liver toxicity for PFOS and PFOA are 
neurotoxicity and immunotoxicity (Dewitt et al., 2012; Viberg and Eriksson, 2011). Both PFOS 
and PFOA affect peroxisome proliferator activated receptors (PPARs), which constitute a 
group of nuclear receptor proteins that function as transcription factors and thus regulate 
gene expression (Viberg and Eriksson, 2011).  
The majority of developmental toxicology studies involved in utero exposure of PFOS and 
PFOA in rodents. Exposure to these compounds during the gestational period has caused 
toxic effects in both the foetuses and new-born pups. For high exposures, birth defects have 
been seen in both rats and mice (Thibodeaux et al., 2003), as well as reduced postnatal 
survival of their neonates and delays in growth and development in the surviving pups (Lau 
et al., 2004). Gestational exposure to PFOS can alter the thyroid hormone system in both rats 
and mice during development, and can be one of the mechanisms of action behind the 
developmental toxicity of PFOS (Viberg and Ericsson, 2011).  
Several epidemiological studies have been conducted to evaluate the impact on humans. 
In occupational studies, the outcome of PFAS exposures have been inconsistent, and no 
clear causal effect has been established. Steenland et al. (2010) conclude that the data are 
insufficient to draw firm conclusions about adverse health outcomes. By contrast in a large 
population-based study (The C8 Health Project, Little Hocking, Ohio, USA; Frisbee et al, 
2009), of a population exposed to high concentrations, significant positive associations were 
observed in children and adolescents between serum concentrations of PFOA and PFOS and 
total serum cholesterol, low-density lipoprotein cholesterol and thyroxine (total T4). A 
significant reduction in calculated thyroid hormone (T3) uptake was also observed (Knox et 
al., 2011). It should be noted that these exposures were atypical and thus their relevance to 
more normal exposure is not clear. In the US National Health and Nutritional Examination 
Survey (NHANES), elevated serum concentrations of PFASs were associated with chronic 
kidney disease (p<0.0001) (Shankar et al., 2011). Interestingly, a study conducted in the 
Faroe Islands reported an association between PFAS serum concentrations and lower 
antibody responses to childhood immunization. Reduced antibody concentrations can 
impair long-term protection (Grandjean et al., 2012). 
Due to the developmental toxicology reported in animal studies of PFASs, there has been a 
focus on human developmental outcomes such as birth weight and length, and head 
circumference (Olsen et al., 2009). The overall picture that has emerged suggests that PFASs 
exposure is not associated with any clinical relevant birth outcomes, in spite of a recently 
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reported negative correlation between maternal PFOS concentrations and fetal plasma T3 
levels (r=-0.41, p<0.05 after adjustment; Kim et al., 2011a) 
One of the challenges in interpreting these studies concerns differences in half-lives of these 
chemicals in humans, and as observed in animal research models. For the latter, the 
exposure doses used were generally considerably higher than what has been reported for 
the general human population. Information about long-term chronic exposure to low doses 
or of combined effects would better reflect the real exposure experienced by wildlife and 
humans, however this information is scarce.  
 
1.5.2 cVMS 
The majority of reports that investigate the absorption, excretion and toxicity of D4 and D5 
have involved experimental animals. Based on this, the amount of cVMS absorbed differs 
between the three uptake routes: inhalation, dermal contact and oral ingestion. In animals, 
around 5% of inhaled D4 and 3% of D5 is absorbed; the corresponding value for D4 in 
humans is 6-17%. When administered to animals in corn oil, 52% (D4) and 20% (D5) are 
absorbed (Brooke et al., 2009a,b). In both rats and humans, dermal uptake is relatively low 
for D4 [<1% (rat) and 0.5% (human) of the applied dose]; for D5 the corresponding human 
value is 0.04% (Jovanovic et al., 2008). Based on the D4 and D5 data, the inhalation 
absorption for D6 is estimated as 3 %. The oral bioavailability of the latter appears moderate 
(15%), and its dermal absorption is expected to be around 0.1% (Brooke et al., 2009c). 
As mentioned in Section 1.2.2, most of cVMS applied to the skin (90%) volatilize rapidly due 
to their high volatility (Reddy et al., 2007; Jovanovic et al., 2008). Thus inhalation after 
evaporation from the skin could be an exposure source (although suspected to be minimally 
so). Absorbed cVMS distribute widely in the body (Kala et al, 1998). The cVMS are highly 
lipophilic, with considerable fat-to-blood partition coefficients (in rats;~2000 and 500 for D5 
and D4, respectively and likely similar in humans), leading to storage in lipid tissues (Plotzke 
et al., 2000; Andersen et al., 2001; Tobin et al., 2008). After inhalation or dermal exposures of 
D4 and D5, cVMS are eliminated through respiration (Andersen et al., 2001; Tobin et al., 
2008), or by way of metabolic degradation (excretion by urine) (Varaprath et al., 2003). 
Urinary excretion as water-soluble metabolites (silanols) and exhalation of the parent 
compounds are the main elimination routes and forms in experimental animals, with loss by 
faeces being minor (Brooke et al., 2009a,b). Unlike D4 and D5, most of D6 is eliminated 
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unchanged in exhaled air. No parent compounds could be detected in urine when the 
metabolic transformation of D5 and the linear siloxane hexamethyldisiloxane was 
investigated (Varaprath et al., 2003). Transformation products for both these two 
compounds and also D4 (Varaprath et al., 1999) included the common metabolite 
Me2Si(OH)2 (among other products), which reduces the suitability of urine for the 
determination of cVMS. The half-life of D5 in male and female rats depended on dose, 
gender, and number of repeated exposures and differed between tissues. The following 
half-lives (t1/2) for a single 6-h exposure of females were typical: 50 h (plasma), 80 h (liver and 
lung), and 495 h in fat; t1/2 values for males were mostly longer (Tobin et al., 2008). Population 
half-lives have recently been reported for retired workers in a manufacturing plant in China 
(Xu et al., 2012); they increased with increasing number of Si-O bonds and ranged from 2.34 
(D4) to 3.15 (D6).  
The mammalian toxicology of D4, D5 and D6 has been summarized by Brooke et al. (2009a-
c). Most of the studies have been conducted for D4. Exposures to D4 by oral or inhalation 
administration caused several biological responses in rats, such as estrogen mimicry (McKim 
et al., 2001) and liver enlargement. As a consequence, D4 has been replaced in many 
formulations by D5 (Reddy et al., 2008; Brooke et al., 2009a), even though liver enlargement 
has also been observed for D5. There is some evidence that D4 (but not D5) could lead to 
impaired fertility in rats, although the suggested reproductive mode of action involved 
would likely not be relevant for humans (Siddiqui et al., 2007a,b). Specific fetal 
developmental effects were not observed. The no observed adverse effect level (NOAEL) 
estimate for fertility effects based on rat studies for D4 (105 mg/kg/day; also assigned to D5) 
was considerably higher than that at which a toxicologically significant liver enlargement 
was seen for both (NOAEL of 19 mg/kg/day) (Brooke et al., 2009a,b). Thus the latter outcome 
is likely the primary systemic health effect relevant for humans. Compared to D4 and D5, the 
magnitude of liver enlargement due to D6 was relatively small. Overall, no toxicological 
hazards have been identified for D6 (Brooke et al., 2009c).  
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2. STUDY OBJECTIVES 
The work described had two primary objectives. 1. Assess maternal and new-born exposure 
to perfluoroalkyl substances in regions for which this information was lacking (no or limited 
data), namely South Africa, Uzbekistan and arctic Russia. 2. Quantify cyclic methylsiloxanes 
in blood plasma of pregnant and postmenopausal women. 
 
More specifically the subgoals were to assess:  
 Geographical differences in PFAS exposures in South Africa (rural versus urban site 
comparison of maternal serum and cord blood concentrations) (Paper I);  
 Distribution of PFAS between whole blood and plasma from Uzbekistani and Russian 
delivering women and their new-borns (cord blood) (Paper II); 
 Relative abundance of isomers of PFOS and FOSA (Paper II);  
 Determine cVMS plasma concentrations in pregnant and postmenopausal women 





3. MATERIALS AND METHODS 
3.1 STUDY POPULATIONS AND SAMPLING DETAILS  
This thesis was based on samples from study populations in four different countries.  
3.1.1 The South African study (Paper I) 
The South Africa study group consisted of 71 delivering women and their new-borns, of 
whom 58 also provided a cord-blood sample. Participating women were recruited from 
those who presented for delivery at provincial delivering hospitals, and represented six 
different South African communities. The locations included (see Figure 5): the city of 
Johannesburg; industrial communities dominated by coal mining, stainless steel 
production, fishing, and gold mining; and malaria endemic communities (one coastal and 
one inland). In addition all women answered a socioeconomic questionnaire (see 
Appendix 1). The majority of the participants were of African Black ethnicity and were of 
comparable economic status. Maternal age ranged from 14-41 y (mean: 25 y). Blood samples 




Figure 5. Geographical locations of study sites in South Africa: Site 2 = urban (Johannesburg); 
Site 3 = industrial; Site 4 = Atlantic Ocean; Site 5 = mining; Site 6 = coastal malaria area; Site 
7 = inland malaria area.  
 
3.1.2 The Russian and Uzbekistan study (Paper II) 
Sampling of human blood was undertaken in parallel with the dietary and lifestyle surveys 
of the GEF/UNEP/AMAP/RAIPON project “Persistent Toxic Substances (PTS), Food Security 
and Indigenous Peoples of the Russian North” (AMAP, 2004b). The sampling period in the 
Russian Arctic (city of Norilsk) was from October to December 2001, and April to June 2002 
in the Aral region of Uzbekistan (see Figure 6 for map). All delivering women were invited to 
participate when in the hospital delivery departments. Mothers from Norilsk city (Taimyr 
okrug of Krasnoyarsk kraj; n=7) were non-indigenous. Mothers from Urgench (n=6) and 
Khazarasp cities (n=4) (Khorezm oblast, Uzbekistan, about 200 km from the Aral Sea) were 
indigenous Uzbeks. The maternal median age at delivery was 24 (range 24-28) and 25 (range 
21-41), respectively for the Norilsk and Uzbekistan study groups. Of the Uzbekistan mothers 
60% had 2-8 children, while 71% of the Norilsk mothers had one child and 29% had two 
(means of 2.7 and 1.3 respectively). Blood was collected from mothers during the first three 
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days after delivery. Cord blood was sampled immediately after tying and cutting off the 
umbilical cord. For whole-blood sampling, Becton Dickinson Vacutainer System (USA) with 
K2-EDTA was used (BD 366457). An aliquot of whole blood was centrifuged at 3 000 rpm to 
separate blood cells from plasma. Cord blood was treated in the same manner.  
 
Figure 6. Map of the Russian Arctic and Uzbekistan with the regions involved in this study 
highlighted (AMAP, 2004b). 
 
3.1.3 The NOWAC and MISA cohorts (Paper III) 
The Norwegian Women and Cancer study (NOWAC) is a prospective cohort study, which 
consists of more than 172 000 women who answered detailed questionnaires regarding 
their diet and lifestyle (Lund et al., 2008). From the original cohort, 50 000 women (born 
between 1943 and 1957) were recruited randomly to the NOWAC postgenome study 
(Dumeaux et al., 2008). The women also donated blood samples (blood was drawn in 2005 
into Greiner Bio-One sodium citrate coagulation tubes), and from a randomly selected batch 
of 500, 332 plasma samples were analysed with respect to paraben content (Sandanger et 
al., 2011). From this batch of 332 women, 94 samples were randomly selected and analysed 
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with respect to cVMS contents. The participating women were 48 to 62 years old, and thus 
may be designated postmenopausal. The NOWAC participants were drawn from a cohort 
for whom the external validity has been confirmed, and thus the women were 
representative of the Norwegian women at their age (Lund et al., 2003). Information on use 
of PCPs was ascertained from a questionnaire that was self-administered just before 
enrolment and prior to the blood sampling (for details see Sandanger et al., 2011 and Lund 
et al., 2008), and thus does not specifically apply to the day of sampling. The questionnaire 
also sought information about breast implants.  
The North Norwegian Mother-and-child Study [also referred to as the MISA Study 
(Miljøgifter i svangerskapet og ammeperioden)] is a longitudinal cohort study which 
consists of 515 women who have answered detailed questionnaires regarding their diet and 
lifestyle. Pregnant women in the study area were invited by written invitation administrated 
by ultrasound clinics personnel or during midwife consultations (Hansen et al., 2010). From 
June 2007 to March 2009, 2600 women were invited, 609 responded, 557 were registered, 
542 gave a blood sample, and 27 were excluded because of the lack of written consent. Thus, 
515 women initially were included in the study. Serum samples were collected in BD 
Vacutainers (SST II Plus Advance 10/8.5 ml), however testing of extracts from various sample 
collection tubes revealed the presence of high concentrations of cVMS in these specific 
vacutainers. At the end of the recruitment period, it was possible to collect a small number 
(n = 17) of plasma samples and red blood cell (RBC) fractions for cVMS analysis using BD 
Vacutainers (K2E 10.8 mg, 6.0 mL) tubes. The sampling period was between February and 
May 2009, during week 11 to week 23 of pregnancy. 
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3.2 ANALYTICAL METHODS 
3.2.1 Analysis of PFAS 
The analytical details are provided in Papers I and II, and only a brief overview is provided 
here. The plasma/serum and whole blood extraction and clean-up methods for the PFASs 
were similar in Papers I and II, and involved modifying the methods described by Powley et 
al. (2005). In short, internal standards were added to plasma, serum or whole blood, and the 
sample was extracted with methanol. The extract was cleaned up with acidified EnviCarb. 
Before analysis recovery standard was added. In Paper I, the sample components were 
separated by HPLC and quantified by mass spectrometry (QToF, Waters), while the Paper II 
analyses were achieved by ultra high pressure liquid chromatography triple-quadrupole 
mass-spectrometry (UHPLC-MS/MS, Thermo Scientific). In Paper I, only two 13C labelled 
internal standards (PFOS and PFOA) were used for quantification. In the Paper II work, 
multiple 13C- labelled internal standards were used (specifically; PFOS, perfluorooctane 
sulfonamide (FOSA), perfluorobutanoic acid (PFBA), perfluorohexanoic acid (PFHxA), PFOA, 
perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDA), perfluoroundecanoic acid 
(PFUnDA), and perfluorododecanoic acid (PFDoDA)) and 18O for PFHxS.  
 
3.2.2 Analysis of cVMS 
To a known amount of plasma or RBC fraction, mass-labelled internal standards were added 
together with 1 mL of hexane. After shaking and centrifugation, a recovery standard was 
added to a known aliquot. Subsequently, the chromatographic analyses of the NOWAC 
samples were performed on a HP 6890 series gas chromatograph, and the isomer 
identification was done on a HP 5973 mass selective detector (Agilent). The 
chromatographic analysis of the MISA samples was achieved with an Agilent 5890N gas 
chromatograph, and the isomer identification was conducted by high-resolution mass 
spectrometry on a Waters Autospec-V Ultima in positive electron ionization mode (EI+, 35 






3.3 STATISTICAL ANALYSIS 
Statistical analyses were carried out using the Data Analysis and Statistical Software (STATA) 
package versions 10.0 (Paper I) and 12.0 (Papers II). In the Paper III data analysis, the 
Statistical Analysis System (SAS) version 9.0 was used. Details of the statistical approaches 
are described in the respective papers together with the different approaches used for 
calculating limit of detection (LOD), limit of quantification (LOQ) and method detection limit 
(MDL). Due to the non-normal distribution of the contaminant concentrations, log-
transformed values (base 10) were used in the statistical analyses in Paper I. To assess 
differences between study sites and cohorts, non-parametric tests were used in Paper II.  
 
 
3.4 ETHICAL CONSIDERATIONS 
Paper I 
An ethics clearance certificate (Protocol Number M040314) was granted for the study by the 
Committee for Research on Human Subjects of the University of the Witwatersrand, 
Johannesburg, South Africa. In addition, informed written consent was obtained from each 
participant prior to inclusion in the study. 
 
Paper II 
The study protocol, training of personnel and the sample collection strategy concurred 
according to those adopted by the AMAP Human Health Assessment Group (AMAP, 1998). 
The study protocol was also approved by the Ethical Committee at the Pasteur Institute, St 
Petersburg (international reference # T5096). Written informed consent was obtained from 
the participating delivering women. 
 
Paper III 
The NOWAC cohort secured approval from The Regional Committee for Medical Research 
Ethics and the Norwegian Data Inspectorate for the basic collection and storing of 
questionnaire information, blood samples and tumour tissue from present. All women 
completed an informed consent for later linkages to the Cancer Registry of Norway, the 
Norwegian Mammographic Screening Programme, and the register of death certificates by 
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Statistics Norway (Dumeaux et al., 2008; Lund et al., 2008). Each sub-project within the 
NOWAC cohort has received approval from the Regional Committee for Medical Research 
Ethics. 
The MISA study was also approved by the Regional Committee for Medical Research Ethics 
and the Norwegian Data Inspectorate. Participation was voluntary, and the women signed 
an informed consent form. 
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4. RESULTS – SUMMARY OF PAPERS 
4.1 PAPER I 
Perfluorinated compounds in maternal serum and cord blood from selected areas of 
South Africa: results of a pilot study 
Because the information about PFAS concentrations in humans in the southern hemisphere 
was sparse, this study was designed to assess them in serum from delivering women and 
cord blood from selected areas of South Africa. The majority of the participants were of 
African Black ethnicity with a similar economic status. The reported PFAS concentrations 
were low, where PFOS was the most abundant compound (median of 1.6 ng/mL, with a 
range <0.1 - 15.9 ng/mL and LOD = 0.1 ng/mL) followed by PFOA (median of 1.3 ng/mL, 
range 0.17-8.5 ng/mL). Concentrations in umbilical cord samples were similar to maternal 
serum. Linear PFOS in maternal samples accounted for 58% of total PFOS, and this was 
comparable to that reported for Australian women (59%) but lower than reported in a 
Vietnamese study (83%). There were significant differences (p ≤ 0.05) in maternal PFOS 
concentrations between the communities, with the highest concentrations observed in 
urban and semi-urban areas. The data suggest different exposure patterns for these 
compounds compared to other countries.  
 
 
4.2 PAPER II 
Partition of perfluoroalkyl substances (PFAS) in whole blood and plasma, assessed in 
maternal and umbilical cord samples from inhabitants of arctic Russia and Uzbekistan 
The Norilsk mothers (living in the Russian Arctic) had significantly higher plasma PFOS 
concentrations, with a median of 11.0 ng/mL (range 5.56-14.5 ng/mL) compared to 0.23 
ng/mL (range < 0.08 - 0.89 and MDL = 0.08) for the Uzbekistani women; PFOS was the only 
PFAS present in more than 80% of the samples for the latter group.  
Partition between the different compartments of blood was investigated for the Norilsk 
samples only. The plasma-to-whole blood ratio for ionic PFASs in delivering women were 
somewhat lower (1.6) than reported elsewhere for adults (>2). The corresponding ratios for 
umbilical cord samples were somewhat higher. In both instances, the observed ratios were 
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similar to those calculated a priori from known blood plasma and cell volumes. FOSA had a 
different distribution that reflected its acid-base properties, with the major amount residing 
in the blood cell fraction. For both carboxylate and sulfonate PFASs, increasing carbon chain 
length correlated with higher maternal-cord ratios for both whole blood and plasma. This 
suggests decreased placental transfer. The median percentages of linear PFOS in plasma 
and whole blood were comparable (50.5 and 46.6, respectively) and lower than reported for 
the manufactured technical mixture (70%). A semi-quantitative determination for FOSA 
yielded even lower values (44.6% in plasma and 40.8% in whole blood). The observation that 
a large fraction of FOSA is associated with the cell fraction implies that the body burden of 
this compound has been underestimated because until now plasma (or serum) was the 
body fluid mainly monitored. This has led to an underestimation of exposure. 
 
 
4.3 PAPER III 
Plasma concentration of cyclic volatile methylsiloxanes (cVMS) in pregnant and 
postmenopausal Norwegian women and self-reported use of personal care products 
(PCPs)  
The wide use of silicones and the ubiquitous presence of cVMS in laboratory air makes their 
analysis challenging. Several procedures were implemented to avoid inadverted 
contamination of the samples.  
For the NOWAC samples, more than 85% of the women had D4 concentrations above the 
LOQ (2.74 ng/mL), while the detection frequency was only 18% for the MISA participants. 
The highest cVMS concentrations were observed for the NOWAC middle-aged women. In 
both cohorts, D4 was the most prominent compound with maximum plasma 
concentrations of 12.7 ng/mL (NOWAC) and 2.92 ng/mL (MISA). The other investigated 
cVMS, namely D5 and D6, were below the detection limit in most of the samples. There were 
no significant correlations between the concentration of D4 and the reported total body 
cream use, however the median increased with increasing percentage of body creams. 
Sampling period (2005 versus 2009) and/or age of the women could explain the differences 






The reported PFAS concentrations in Paper I and II show large variations and predictors that 
may explain these differences are discussed below.   
Emission history and its effect on place of residency and time of sampling (including birth 
year of the mother) seems to be a relevant predictor for maternal PFOS concentration 
(implied by Figures 3 and 7). The observed PFOS (sum of branched and linear) and PFOA 
concentrations for arctic Russia, Uzbekistan and South Africa have also been compared to 
reports from other countries. The maternal sample concentrations in these figures represent 
the exposure at the end of pregnancy or at delivery, except for Beesoon et al. (2011) for 
which the samples were from gestational week 15. Other than the South African data, the 
concentrations depicted in Figures 7 and 8 are for Northern Hemisphere countries. With 
respect to PFAS emissions, the developed countries are more affected; this is reflected in the 
higher concentrations compared to undeveloped countries (Lau et al., 2007; Martin et al., 
2010). Clearly geographical localisation and living standard are strong predictors, and hence 
Uzbekistan and South Africa are less impacted compared to developed countries. The PFAS 
concentrations also reflect the year(s) of sampling, however interpretation of the time 
trends in Figure 7 must been done with care. It seems that the PFOS concentrations in 
delivering women residing in countries in the northern hemisphere have decreased over 
time. This is in agreement with that observed for general population study groups in the 
USA and Norway (see Section 1.4.2), as well as the reduction in production (see Figure 3). 
Consequently, the year of sampling should have an impact on the concentration magnitude 
observed. This trend is less prominent for PFOA, since its production continues by the 
telomerization manufacturing process (Benskin et al., 2010). Also, PFOA seems to be more 
ubiquitously distributed (Vestergren and Cousins, 2009). This is supported by our 
observation that South Africa concentrations were of comparable magnitude with values 
from Northern hemisphere countries (see Figure 8). The low bioaccumulation potential of 
PFOA relative to PFOS (Conder et al., 2008) presumably contributes to the narrow 
concentration ranges.  
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In the South African study we investigated the association between maternal age and PFAS 
concentration, and found no significant relationship. Dependence on age (and also sex) has 
been observed in some studies (Ericson et al., 2007; Hölzer et al., 2008), but not in others 
(Calafat et al., 2007; Midasch et al., 2006). For legacy POPs like PCBs, recent modelling has 
emphasized the importance of considering birth year and sampling year in relation to 
emission history (Quinn et al., 2011). In a cross-sectional study it is important to evaluate the 
PFAS concentrations in relation to age structure of the cohort/maternal age, year of 
sampling and historic emissions. 
 
Figure 7. PFOS concentrations in plasma (p) or serum (s) of delivering women and umbilical 
cord blood (UCB). All studies had the same matrices for maternal and UCB samples, except 
for South-Africa where maternal serum and UCB whole blood (multiplied with a factor of 2) 
were compared. For Russia, Uzbekistan and South Africa sum-PFOS (i.e., liear and branched) 
is reported. The figure is based on the following publications: Denmark, Fei et al., 2007; Faroe 
Island, Needham et al., 2011; Russia, Hanssen et al., 2013; Uzbekistan, Hanssen et al., 2013; 
Japan, Inoue et al., 2004; Germany, Midasch et al., 2007; Canada, Monroy et al., 2008; South 
Africa, Hanssen et al., 2010, South Korea, Kim et al., 2011b, Canada, Beesoon et al., 2011, 









































































































































































































































Figure 8. PFOA concentrations in plasma (p) or serum (s) of delivering women, and in 
umbilical cord blood (UCB). All studies had the same matrices for maternal and UCB samples, 
except for South-Africa where maternal serum and UCB whole blood (multiplied with a 
factor of 2) were compared. N.D, not detected. See legend to Figure 8 for list of publications 
consulted. 
 
Higher PFAS concentrations in samples from Norilsk compared to Uzbekistan indicate a 
difference in exposure. To help in the interpretation of this finding, a brief discussion ensues 
about identified sources for legacy POPs in the study communities. From the AMAP report 
(2004b), we know that the delivering women in Norilsk (both indigenous and non-
indigenous) had elevated PCB concentrations, while they were considerably lower for the 
Uzbekistani group. By contrast, the pesticide derivative p,p-DDE was considerably higher for 
the latter subjects. This suggests differences in exposure scenarios. The Uzbekistani women 
were known to be exposed to pesticides from local use and this was reflected especially in 
their plasma concentrations of p,p-DDE (Sandanger et al., 2009). It is well known that Arctic 
populations are affected by LRT and that traditional foods such as fish are consumed as well 





































































































































































































































organochlorine pesticides due to their bioaccumulation and biomagnification in these 
species (AMAP 1998, 2003, 2004a,b; Ostertag et al., 2009). 
As illustrated by the plasma concentrations depicted in Figure 9, PFAS are known to be 
present in the Arctic and , in addition to local sources, LRT is suspected (see Section 1.3.1). 
The presence of PFOS and PFOA in blood samples from Norilsk with concentrations of 
comparable magnitude to those reported for Northern Hemisphere industrialised countries 
(see Figures 7 and 8), support this interpretation. The seven women investigated in Norilsk 
were non-indigenous and mostly consumed store bought foods (primarily non-local). Plant 
cultivation in Norilsk area was minimal. Because of regional reindeer breeding, fishing and 
hunting activities, there was some consumption of tundra reindeer, ptarmigan, and fish. The 
Uzbekistani women had a diet that featured a variety of items produced locally (e.g., meat, 
poultry, fish, cereal, fruits and vegetables), and the reported PFAS concentrations for these 
women were low (see Figures 8 and 9; most of the samples had PFOA concentrations below 
the MDL). There is no information available on the content of PFAS in food and food 
packaging from Russia and Uzbekistan. It is suspected that it was low in prior to and during 
the sampling period (personal communication, A.A.Dudarev). Diet has been suggested as 
the major source and thus a likely predictor for PFAS concentrations in body fluids 
(Vestergren et al., 2012), and might thus serve as a reflection of the emission history. Since 
the phase-out of POSF production, diet as a direct exposure source will become a more 
prominent predictor compared to more indirect sources such as dust and indoor air. The 
latter are and will be influenced by the phase-out of PFASs from consumer products. 
Although environmental measurements for both these areas are scarce and as already 
mentioned, it is likely that the Norilsk area is affected somewhat by its industrialization in 
addition to LRT. One report on PFASs in snow from arctic Russia confirms the latter (Saez et 
al., 2008). A delay in LRT might be a possibility and, if so, the concentrations in the Arctic 
environment might even increase after the phase out (Armitage et al., 2009). Consequently, 
the concentrations of PFAS in the diets of residents of the Arctic might thus rise for some 
time based on this scenario (i.e., emission history is important). The low maternal plasma 
concentrations observed confirm that the environment in Uzbekistan is not contaminated 
with PFAS. 
The PFASs emission in the Southern hemisphere is limited (Hanssen et al., 2010, Paper III). In 
the South Africa population studied, the PFOS concentrations were low, while those of PFOA 
were comparable to Norilsk (Figures 7 and 8). For the South-Africa study groups, the 
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observed concentrations of PFOS and PFOA were significantly higher in semi urban/urban 
versus rural areas. Differences in diet, housing and use of consumer products were important 
predictors of the reported concentrations.  
 
 
Figure 9. PFOS concentrations (μg/L) in plasma of mothers, pregnant women and women of 
child-bearing age in the circumpolar countries (AMAP, 2009, revised 2012). The wording 
“serum lipid” in the figure does not apply.  
 
It was not possible to evaluate breastfeeding as a predictor for maternal PFAS 
concentrations due to the quality of this information in our studies. Even though the PFASs 
concentration in breast milk are considerably lower than maternal serum, the transfer to the 
child by breast milk is still considered significant (Kärrman et al., 2007b). This suggest that 
the number of children (see placental transfer below) and breastfeeding would affect the 
maternal PFAS concentration in blood.  
The PFASs in human blood samples most frequently reported in recent publications besides 
PFOA and PFOA are PFHxS and long chain PFCAs such as PFNA, PFDcA and PFUnDA. Ideally, 
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the presence of PFNA and PFUnDA in the Norilsk samples could indicate an exposure source 
from an ECF production, since telomerisation yield only even numbered carbon chains. 
However breakdown products of telomers, such as 8:2 FTOH and 10:2 FTOH, could also yield 
these compounds (Ellis et al., 2004; Sinclair and Kannan, 2006). Even though the 
concentrations of PFASs other than PFOS and PFOA are considerably lower, it is of 
importance to continue monitoring them. Rationale for this includes the observation by 
Haug et al. (2009) and Glynn et al. (2012) that the decline in concentration of ‘other’ PFASs 
of the POSF production was not as rapid after the phase-out. Concern remains about 
continued human exposure, especially now that PFOS production in China is suspected (see 
Section 1.4.2). The production volumes (<300 tonnes per year) in China are lower than those 
previously reported for 3M (see Figure 3) (Lim et al., 2011), however the impact on the 
environment of neighbouring countries like Uzbekistan and Russia cannot be disregarded.  
In conclusion, many of the exposure source factors and body-fluid contaminant 
concentration predictors discussed in Section 1.4.2 for PFASs appear to be reflected in the 
country differences observed in the present study.  
 
5.1.2 Blood matrices 
As mentioned in Section 1.4.2, serum (or plasma) has been the matrix of choice for 
biomonitoring of PFASs. Whole blood is considered a difficult matrix and is not routinely 
used in clinical chemistry measurements (Ehresman et al., 2007). Using serum or plasma for 
legacy POPs analysis has been appropriate since these compounds are associated with the 
lipid fraction. The ability PFASs have to bind to albumin also suggests that serum or plasma 
is the appropriate matrix for these compounds. However, the question to ask is: do we get 
the complete picture of exposure analysing only serum or plasma? D’Eon and Mabury (2010) 
reported that in paired whole blood and plasma samples from rats, the concentration of 
mono-perfluorinated phosphonic acids (mono-PFPA) was equal in plasma and whole blood. 
This suggested that this compound may associate with blood cells, leading to an 
underestimation of their concentration in serum and plasma. Using appropriate packed cell 
and plasma volumes for neonates and pregnant women at term, plasma-to-whole blood 
dilution factors were calculated in the current project. These values were 1.6 (maternal) and 
2.5 (umbilical cord), and were in good agreement with those observed for PFOA, PFNA, 
PFHxS and PFOS (see Figure 10). The observed ratio for PFUnDA was somewhat lower than 
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predicted in both instances [medians of 1.44 (maternal) and 1.86 (cord)], which might have 
been biased by its low detection frequency. Indeed plasma or serum seems to be a suitable 
matrix for the majority of ionic PFASs, and thus nothing seems to be lost when the cell 
fraction is removed. 
For FOSA the ratios were distinctly different [medians of 0.14 (maternal) and 0.78 (cord)] (see 
Figure 10). Using the pKa of 6.27 for FOSA and the pH of blood as 7.37, calculations showed 
that approximately 7% of the compound would be uncharged or in a neutral form, and this 
estimate is close to what we observed in the plasma fraction. This implies that most of the 
FOSA resides in the blood cell fraction as the sulfonamidate ion, which concurs with the 
maternal whole blood/plasma concentration ratio observed of 7.14 (i.e., 1/0.14). This 
preference for whole blood is also reflected in the cord whole blood/plasma concentration 
ratio, but less dramatically so (see also 5.1.3). It has been pointed out that the negative 
charge of this ion is stabilized by resonance and is thereby reduced [i.e., its negative point 
charge is spread over the nitrogen and oxygen atoms of the sulfonamidate moiety, (–SO2–
NH2)]. Additional details are provided in Paper II.  
Since most of FOSA occurs in the cellular compartment of blood and the majority of studies 
have only reported plasma or serum concentrations, exposure to this compound is most 
likely to be underestimated. Clearly this difference in distribution could bias risk assessment 




Figure 10. Plasma-whole blood concentration ratios for PFASs in maternal and umbilical 
cord samples (Norilsk data). The asterisks (*) signifies a statistically significant difference 
(Wilcoxon signed rank test) between cord and maternal samples. The centre line of the box 
represents the median and its top (Q3) and bottom (Q1) the 75th and 25th percentiles, 
respectively; Q3 - Q1 is the interquartile range (IQR); the top and bottom whiskers represent 
± 1.5 IQR; and solid circles denote outliers. . (This figure corresponds to Figure 4 of Paper II.) 
 
5.1.3 Comparison of maternal and cord concentrations 
As seen in Figures 8 and 9, the placenta seems to function as a partial barrier for PFASs, since 
the umbilical cord plasma (or serum) concentrations are generally lower than for the 
mothers for both PFOS and PFOA. Also, and generally speaking, the comparable temporal 
concentration patterns for the mother and neonate samples in these figures suggest that 
the geographic dependences and other exposure risk factors discussed for the mothers in 
Section 5.1.1 appear applicable to the neonates as well. A second general trend in Figures 8 
and 9 is that the PFOS concentrations are considerably higher than PFOA. This reflected in 
both Figure 11 (plasma) and Figure 2 of Paper II (whole blood) since the ratios displayed are 
less than unity. A closer look at the latter figure indicates that the ratio PFOA/PFOS is 


























African data set, even though the PFOS concentrations were relatively low and comparable 
to (maternal serum) or lower than (cord blood) PFOA. This umbilical cord preference for 
PFOA is explained by a higher transplacental transfer efficiency (TTE) (see below). 
 
Figure 11. Abundances of PFASs relative to PFOS in plasma (maternal and umbilical cord; 
Norilsk data). See Figure 10 legend for explanation of the box plot.  
 
Both chain length and functional group are factors that can affect the placental transfer of 
PFASs. Transport by passive diffusion appears prominent, at least for the majority of 
anthropogenic compounds (Syme et al., 2004). Transplacental transfer can alter (increase or 
decrease) during the course of gestation due to changes in placental structure and 
metabolic demand (Cunningham et al., 2010). As illustrated in Figure 12 by the 
maternal/cord plasma concentration ratios and in Figure 3B of Paper II for the same whole 
blood comparison, PFOA seems to cross the placenta more easily than PFOS. The median 
ratio values for plasma for the anionic PFASs ranged 1.2-2.9 (Figure 12), while those for 
whole blood for the same compounds were somewhat higher (1.5-3.3; Figure 3B, Paper II); 
for FOSA, the median values were 0.9 (plasma) and 6.0 (whole blood). Thus the 














blood, with FOSA in plasma a possible exception (see discussion below). The maternal-cord 
concentration plasma ratio has been suggested as a measure of TTE (Beesoon et al., 2011). 
Apparent increases in this ratio for both plasma and whole blood were evident with the 
length of the carbon chain for both the carboxylate and the sulfonate PFASs, as observed by 
others (Beesoon et al., 2011; Gützkow et al., 2011).  
 
 
Figure 12: Maternal-cord concentration ratios for PFASs (Norilsk data) in plasma. (This figure 
corresponds to Figure 3A of Paper II.) See Figure 10 legend for explanation of the box plot. 
 
Clearly FOSA differs from the other PFSAs and PFCAs. It is interesting that for our data set 
the concentrations of FOSA in whole blood relative to plasma in umbilical cord samples do 
not favour the former as strongly as is the case for the mother (see Figure 10; also Table 1 of 
Paper II). Previously reported umbilical cord concentrations of FOSA in serum have been low 
(the majority of the samples had concentrations below the LOD) (Inoue et al., 2004; Apelberg 
et al., 2007). Possibly, FOSA’s distribution between plasma and the cell fraction of blood is 
sensitive to the cellular composition of the latter. Indeed the haematological profile of cord 
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elevated (Lewis et al. 2001). Other factors may influence this distribution as well, such as the 
relatively enhanced levels of certain proteins that occur in cord plasma such as of albumin 




In Paper II, the observed percentages of linear and branched PFOS and FOSA in both whole 
blood and plasma were comparable (median values between 40 and 50%, see Table 1 in 
Paper II)). The percentage branched PFOS diverge from the commercially produced 
products, for which the ratio between linear and branched isomers was 70:30 (Martin et al., 
2010). Our observation suggests that the increased percentage of branched PFOS reflects 
increased branching of the FOSA precursor, and that some of the PFOS exposure is due to 
biotransformation of precursor compounds (Benskin et al., 2009b). 
Although a precursor to PFOS, FOSA itself is a degradation product of Et-FOSE and Et-FOSA 
(Xu et al., 2004; Benskin et al., 2009 b), Et-FOSE/FOSA were produced exclusively by the ECF 
process and consists of both branched and linear isomers in unequal proportion (the linear 
form is most prevalent). The biotransformation of Et-FOSE to FOSA is quite rapid (Fromme 
et al., 2009) and there is a preferential biotransformation of branched Et-FOSA (Benskin et 
al., 2007). This might explain the increased percentage of branched PFOS reported in several 
studies (Kärrman et al., 2007a; Haug et al., 2009; Rylander et al., 2009). Published FOSA 
concentrations in serum or plasma have been low and, as we point out, more likely 
underestimated. Consequently, the percentage branched FOSA could have been difficult to 
estimate.  
The proportion of branched PFOS in umbilical cord samples was addressed both in Papers I 
and II. In Paper I, we report a higher percentage branched PFOS in cord blood (48%) 
(corrected for cell displacement) compared to maternal serum (42%). This is in accordance 
with a study where a more detailed isomer identification was performed (Beesoon et al., 
2011). In Paper II maternal samples had higher percentage of branched PFOS, both in plasma 
and whole blood (respectively, 49 and 53%), compared to cord samples (42 and 47%). These 
results could have been biased by instrumental limitations (UPLC-MS-MS versus. LC-QToF) 
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and time of sampling of maternal blood, but an influence of geographical exposure 
differences, such as direct and indirect exposure, cannot be discounted. 
 
 
5.2 HUMAN BIOMONITORING OF CVMS 
5.2.1 Observed concentrations in perspective   
As indicted in Section 1.4.3, only a few human biomonitoring studies have looked at cVMS 
concentrations in human plasma. For the first time, we reported cVMS concentrations in 
plasma from women randomly selected from the general population. The most prominent 
compound was D4 followed by D5 and then D6; however the latter two were not reported 
for the MISA cohort. The median D4 plasma concentrations for the NOWAC and MISA cohort 
were respectively 4.80 and 2.07 ng/mL. This is somewhat higher than reported for ten 
controls in the study by Flassbeck et al. (2001), where no cVMS were reported above the 
detection limit (2 ng/mL). Flassbeck et al. investigated the cVMS content in blood plasma of 
women with breast implants. They reported D4 as the most prominent compound with 
concentrations ranging from 2 to 50 ng/mL. In a recently published study, cVMS and linear 
siloxanes concentrations were reported in blood plasma from current and previous cVMS 
production facility workers and people living near the plant (Xu et al., 2012). In current 
workers, both D4 and D5 were reported with average >200 ng/g (detection frequency was 
100%). A linear siloxane was the most prominent compound in this group (median 
>400 ng/g). In the control group (community perpendicular to the wind direction of the 
plant; n=58), D4 and D5 were reported in two and three samples respectively with 
concentrations ranging from 1.2-3.6 ng/g (D4) and 2.0-5.0 ng/g (D5). This is comparable to 
that for our NOWAC women, for whom the median concentrations for D4 and D5 were 4.80 
and 1.94 ng/mL respectively. It is worth to mention that in both the study by Flassbeck et al. 
(2001) and Xu et al. (2012), the cVMS exposure is not applicable to the general population.  
Compared to PFASs and legacy POPs, cVMS differ in exposure routes as already indicated in 
Section 1.4.3. Rather than diet, dermal application and inhalation would be the major 
exposure pathways. The low detection frequency of cVMS in the samples from the MISA 
pregnant women together with the small number of participants complicates comparisons 
between the two groups. Nevertheless, some discussion still seems warranted. 
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The NOWAC estimated exposures to cVMS are comparable to the amounts applied by 
United States women in body lotions (respectively, 7.4, 4.0 and 1.0 μg/day for D4, D5 and 
D6, respectively; Horii and Kannan, 2008). By contrast, the estimates by these authors of the 
total D4, D5 and D6 applied in personal care and cosmetics products show quite an 
unrelated pattern (1 080 , 233 000 and 22 000 μg/day, respectively). Dermal absorption rate 
is likely an important determining factor: D4 (0.5 %) > D5 (0.04 %) ≈ D6 (estimated at 0.1 %) 
(see Section 1.5.2). It should be reiterated that prior to the sampling of the NOWAC plasma 
samples, the amount of cVMS registered in Norway was at its maximum (see Figure 13), 
followed by a sharp decline in 2005. This pattern may nevertheless imply that exposures 
were potentially higher for the NOWAC women. However, this figure is incomplete since 
cosmetics containing cVMS were not included in it, and may therefore underestimate 
important potential exposures for the 2005-2009 study period.  
The difference in age between the cohorts (up to 30 years) may also be relevant. Changes in 
skin are a natural consequence of age, and this might lead to a alterations in the 
permeability of chemicals through the skin (Poet and McDougal, 2002; Farage et al., 2008). 
Perhaps higher use of PCPs by the older NOWAC group occurred, or that pregnant women 
are more cautious with respect to use of such products. We cannot disregard the possibility 





Figure 13: Sampling year for NOWAC and MISA cohort and registered imported cVMS in 
Norway. 
 
cVMS exposure risk factors such as breast implants and PCPs use were assessed by 
questionnaires in the NOWAC cohort. As pointed out in Paper III, there was no statistically 
significant trend for the investigated cVMS with respect to daily percentage body surface 
area creamed. Nevertheless, and as indicted in Figure 14, the median D4 concentrations 
increased with the percentage of area skin creamed, however this observation was not 
statistically significant. The absence of breast implants was assessed only for the NOWAC 
subgroup. Lack of extreme values observed for the MISA women suggests their absence or, 































Figure 12. Percentage of area skin creamed versus median concentration of D4 in the 
NOWAC cohort (p = 0.12). 
 
As indicated in Section 5.3.3.2, the ubiquitous presence of cVMS in the laboratory was a 
challenge with respect to conducting the analytical chemistry. In spite of rigorous quality 
assurance steps, the LOQs were rather high (1-2 ng/mL of plasma). It is interesting to note 
that this concentration is two-to-three times higher than those reported for PCB 153 (AMAP, 
2009, revised 2012). Some concern remains therefore about cVMS exposures experienced 
by humans. Furthermore, the short turnover time for cVMS in the body due to their rapid 
metabolism and excretion (as described in section 1.5.2) could lead to bias with respect to 




Both plasma and whole blood seemed to be suitable matrices. [Use of serum was not 
possible due to inadverted contamination from the collection tubes (see Section 5.3.3.2)]. 
One study (Flassbeck et al., 2001) reported higher concentrations in whole blood compared 
to plasma, however the samples were not paired. In paired samples (n=2) we found 
comparable concentrations in the RBC fraction compared to the plasma samples, however 



























to confirm the observations by Flassbeck et al. (2001). Whole blood as an alternative matrix 
for cVMS determination should be investigated further. Based on the observation that D5 in 
animal studies has shown a preference for storage in fat, plasma or whole blood might be 
the most suitable medium. They would be the perferred over urine because D4 and D5 have 
common metabolites (Varaprath et al., 1999, 2003). 
 
 
5.3 CHALLENGES AND LIMITATIONS 
5.3.1 Preamble 
For HBM studies to have an impact, their results must be trustworthy and have validity. This 
is ensured by good study design, quality assurance and quality control procedures. Below 
challenges and limitations relevant for the cohorts presented in this thesis are discussed. 
 
5.3.2 Study design, sample size, and external validity 
In total, five populations are included in the three thesis research papers: delivering women 
from South Africa, Uzbekistan and from Norilsk in Russia; pregnant Norwegian women 
(MISA); and postmenopausal Norwegian women (NOWAC). The common denominator is 
that all studies have a cross-sectional study design. 
For both the original NOWAC and MISA cohorts, the external validity have been discussed 
(respectively, Lund et al., 2003; Hansen, 2011). Since the number of participants from the 
MISA cohort in Paper III was by necessity rather low, therefore so is the external validity. On 
the other hand, the external validity for the cVMS findings for the NOWAC women may be 
rated as good, as this cohort has been shown to be representative of Norwegian women of 
the same age (Lund et al., 2003). As the NOWAC study was not designed to study PCP use, 
bias in terms of product use and pre-selection of women choosing to participate was 
avoided (Sandanger et al., 2011).  
No formal validation of the external validity of South Africa, Russia and Uzbekistan cohorts 
was conducted. The low number of participants from Russia and Uzbekistan made such 




Early reported PFAS concentrations varied widely, and several laboratory round-robins were 
conducted and reported on to resolve underlying analytical challenges. The results of such 
efforts have been published in the peer-review literature, including validation of clean-up 
methods (Reiner et al., 2011). In consequence, the following modifications have helped to 
decrease uncertainty in PFAS analyses: increased number of mass-labelled standards; better 
analytical instrumentation; and awareness of inadvertent contamination from multiple 
sources [e.g., equipment containing PTFE (e.g., Teflon) tubing; and co-elution of compounds 
naturally present in the analytes (e.g., bile acid; Benskin et al., 2007)]; and use of standard 
reference materials. Today the variation is ± 20% or better (Lindström et al., 2009; Reiner et 
al., 2011), which is acceptable. Our results from analysis of standard reference materials 
(SRMs) and participation in round robbins are well within this variation.  
The quantification of branched PFOS and FOSA in Paper II has some limitations. The 
quantification transition used for linear PFOS (49980) is not representative for all of the 
different branched isomers (Berger et al., 2011). Since the isomers are not separated, and no 
separate response factor was calculated for them, there is a possibility of either under or 
overestimation. This discrimination was not apparent in Paper I, since the analysis was done 
on a QToF instrument and the molecular ion was used in quantification. For FOSA, no 
branched isomers are commercially available, which made the isomer quantification in 
Paper II less significant. However, and as suggested by Benskin et al. (2010), analysis of a 
technical mixture can be used as a guideline for estimating the percentage branched. Our 
comparison of the various FOSA profiles (see Supplementary Data Figure S1 of Paper II), 
provided confirmation of the increased amount of branched FOSA in whole blood samples. 
 
5.3.3.2 cVMS 
cVMS analyses were more challenging than PFASs, especially with respect to inadvertent 
contamination and the high volatility of the these compounds. Serum tubes proved to be 
unsuitable due to the “gel” in the tubes that contained large amounts of cVMS. The presence 
of cVMS in PCPs led to initiatives to minimize inadvertent contamination during clean-up 
and analysis, including curtailing personal use. Consequently, we carried out all sample 
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clean-up activities in a clean room facility. To minimize instrumental background, the 
analyses were carried out in the late afternoon of work days and during weekends when the 
human activity in the laboratory was low. To lower the background further, we selected a 
low bleed GC-column (DB WAX ETR) and chose a conservative approach to LOQ calculation 
in response to the multiple indavertent sources of contamination identified. Additional 
precautionary measures adopted during sample preparation are described in Paper III. The 
external validation of the cVMS clean-up and analysis have been established in two round-
robin published exercises (McGoldrick et al., 2011; Warner et al., 2012).  
As alluded to in Section 5.2.2, an unexpected pitfall was encountered. The analysis of serum 
collection tube washings (BD Vacutainers, SST II Plus Advance 10/8.5 ml) showed that 
contamination had occurred. Rinses had high concentration, typically: D4 (111 ng/mL), D5 
(200 ng/mL) and D6 (199 ng/mL) whereas no cVMS was present in similar washings from the 




Berger et al. (2011) showed that the recovery of longer chain PFCAs dissolved in water 
(PFUnDA and PFDoDA) decreased during a storage period of 90 days when were stored in 
polypropylene (PP) bottles at 4°C. Other PFSAs and PFCAs did not show similar behaviour. 
This observation may have implications for the long-term storage of surface active 
compounds such as PFASs. To which degree storage has had an impact on the samples 
analysed in Papers I and II is unknown. All of the plasma samples were stored at -20°C until 
extraction and before analysis. Before an aliquot was taken out, the sample tube was 
thoroughly shaken. The binding of PFCAs to proteins, for example, would likely lower their 
adsorption onto the storage container walls. In a study from the U.S, samples were 
reanalysed after several years of storage at -80°C, and there was no statistical differences in 
either PFOS or PFOA concentrations (Olsen et al., 2007b). This indicated that long term 






No studies with respect to long-time storage of samples, as described for PFASs, have been 
conducted for cVMS. However, the high vapour pressure of cVMS is challenging in 
environmental exposure studies (Brooke et al., 2009b). In a study by Krogseth et al. (2013), 
cVMS concentrations on spiked passive-air sample disks did not decrease after 30 days 
storage at - 20°C. The high fat:blood partition of cVMS (Reddy et al., 2008), which reflects 
their low water solubility, suggest that cVMS may be even more protected from vaporization 




6. CONCLUDING REMARKS 
 A literature review of cross-sectional studies showed that sampling year is an important 
predictor of plasma PFAS concentrations (a decrease with time has occurred since 
phase-out).  
 Exposures to PFASs depends on where you live, and in this study concentrations were 
decreases in the order: remote Arctic Russia, South Africa and Uzbekistan.  
 Compared to the other PFASs studied, the relatively high pKa value of FOSA, which is a 
physicochemical acid-base property, appears to explain its unique distribution between 
plasma and the cellular fraction of blood. Whereas ionic PFASs reside in the plasma 
fraction, the majority of FOSA are in the cellular fraction. 
 The experimental data suggests that the placenta acts as a partial barrier for PFASs, with 
long chain PFASs being more retained than short chain homologs and PFSAs more than 
PFCAs. 
 cVMS concentrations are reported for the first time in Norwegian females randomly 
selected from the general population. 
 The ubiquitous presence of cVMS in the laboratory environment constitutes an 
analytical challenge. 
  Even though the observed cVMS concentrations were close to the detection limit, their 
absolute magnitude exceeded those for certain legacy POPs. Therefore, some concern 
about their presence in the environment and humans remains. 
 The results from the two cohort studies (MISA and NOWAC) can be used for the exposure 




7. FUTURE PERSPECTIVE 
HBM can be time consuming, expensive and requires relatively large sample volumes. This 
is still an issue for monitoring children (including use of the umbilical cord). The challenge 
to overcome this shortcoming requires the continued development of more sensitive 
analytical methods (i.e., lower LODs) and supporting small-sale sample preparation 
technologies. 
Vital information can become lost in the search for new contaminants in HBM studies if the 
matrices of choice are not optimum for the compounds in question. The current work has 
demonstrated that whole blood measurements are essential for estimating the exposure to 
selected PFASs and matrix selection is therefore important for the monitoring of emerging 
contaminants.  
Compounds in PCPs (parabens and siloxanes) are metabolised quite rapidly in humans and 
time of sampling compared to the exposure time could create bias. The timing of specimen 
collection is therefore crucial. Another challenge for substances that are in wide use such as 
the PCPs is inadvertent contamination as demonstrated for CVMS. Other examples are: 
phthalates, bisphenol A, parabens, and linear siloxanes. Working in clean rooms is required, 
and this would limit the number of laboratories able to carry out reliable analytical work 
involved in HBM 
A long standing issue has been how to assess the combined effects of multiple 
environmental contaminants. Compared to 10 years ago new instrumentation and 
techniques has led to a vast list of compounds and over 200 known contaminants are 
present in human blood. A fair question is how will long term exposure to contaminant 
cocktails affect the general population? The number of diseases in which contaminants 
potentially may play a role is increasing in prevalence. This warrants further studies on the 
connection between contaminants and human health. New ways of exploring cause and 
effect are needed. One future perspective might involve a combination of HBM of exposure 
and of effect such as the new approach referred to as “exposome” technology (e.g., use of 
genetic expression). It is thought to be able to capture an assessment of the total exposure 
experienced and aspects of its effect. We are only seeing the beginning of this new scientific 
endeavour and there is a long way to go (Rappaport and Smith, 2010; Rappaport, 2012; 
Vineis et al., 2013). 
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And finally, a consortium to coordinate and harmonise approaches to HBM in Europe has 
been established. This can be an important tool to effectively monitor both exposure to 
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Discussion: An important difference between our work and that by Beesoon et al. (2011) and 
Gützkow et al. (2012) is time of sampling during pregnancy (respectively at delivery, week 
15 and week 37). 
In the study by Gützkow et al.(2012), informed consent was collected in week 37 whereas 
the blood sample was collected immediately after delivery.  
Supplemental: In Table S3: PFUnDA concentration in cord plasma for id code 27 is in the 
table set as 0.02 ng/mL. The correct value should be < 0.05 ng/mL. 
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MEDICAL RESEARCH COUNCIL 
 
 
ENVIRONMENT & REPRODUCTIVE HEALTH STUDY 
  
  
This questionnaire is part of the Medical Research Council environment and 
reproductive health study. We would like to request that you take the time to 
answer the questionnaire with the assistance of trained interviewer. We thank 
you in advance for your participation. 
 
 
If you have questions or need more information, please do not hesitate to call 




SUBJECT STUDY NUMBER …………  AREA STUDY CODE………. 
 
 
Clinic Name: ............................................... 
 











SECTION A: BACKGROUND DETAILS         
 
In this section we would like to obtain a few background details about yourself.  
 
1.  What is your first name? ...............................……………  
         
2.  What is your surname? .................................…………….  
  
 




.......................................................   
  
4.  What is your present contact telephone  number 
……………………………………  
  




Day …………………………  
 
Month   ……………………… 
 
Year    ………………………….   
                
6. How many children do you already have:    
  
…………………………………   
  
7. How many daughters do you have:  number: …… ages: ………….  
  
  
8. How many sons do you have:  number: …………..ages …………..  
 
9. What language do you usually speak at home (please circle!)  
   
1.  English  
        
2.  Afrikaans  
  
3.  Xhosa  
       
4.  Sotho  
  
5.  Zulu  
  
6.  Other (please specify) …………………………….  
 3
10.  What is your race/population group? (please circle!) 
 
(This question is being asked because in South Africa population group is still closely 
linked to economic status, which in turn is closely linked to certain environmental 
factors.) 
 
 1.  African black  
 
 2.  Coloured  
 
 3.  Asian  
 
 4.  White   
 
  
11.  What is your nationality?  …………………………………….  
  
  
12.  How would you describe your place of residence  (please circle one 
answer only)  
      
1.  Urban (city) 
  
2.  Rural (farming community)  
  
  3.  Peri urban  (close to the city)  
  
4.  Informal settlement  
  
5.  Close to industrial site: (please specify)  
   ………………………………………………  
  
  6.  Don’t Know         
 
  
13.  How long have you lived at your present home address?  
   
           Years ………………………  
  
 Months ……………………             
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SECTION B: HOUSING            
In this section we would like to have some information about the household   
you presently live in  
  
1.  Is this home:  (please circle)         
 
  
       1. Owned  
  
       2. Rented  
  
 
2.  How would you describe your home? (please circle)  
  
       1. House  
  
       2. Flat  
  
       3. Backyard dwelling  
  
       4. Informal house (shack)  
  
       5. Other (please specify)  .................   
          
  
3.  How many rooms, not counting the kitchen, bathroom or toilet, does this home   
  
 have?   …………………………………………………  
  
               
4.  What fuel is used most of the time for cooking? (please circle)  
     
       1.  Electricity   
  
       2.  Paraffin  
  
       3.  Gas  
  
       4.  Wood  
  
       5.  Coal  
  
       6.  Car batteries  
  
       7.  Other (please specify) .....................……..  
    
5.  What fuel is used most of the time for heating the home? (please circle)           
     
1.  Electricity    
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2.  Paraffin  
  
3.  Gas  
  
4.  Wood  
  
5.  Coal  
  
6.  Car batteries  
  
7.  None  
  
Other (please specify)  ...........................  
  
6.  Does anyone regularly smoke at home? (please circle!)      
  
1.  Yes   
 
2.  No  
   
7.  How many people regularly smoke cigarettes in the home? (At least one  
  cigarette per day at home)  
      ........................………   
  
8.  Did you smoke: (please circle)  
  
1.  Before pregnancy  
  
2  During pregnancy  
  
3.  Both  
  
4.  Number of cigarettes daily   
  
 
9.  Where do you get your drinking water from most of the time? (please circle)  
     
1.  Indoor tap  
  
2.  Outdoor tap  
  
3.  Rainwater tank 
 
4.  Borehole   
   
5.  River/stream  
  
6.  Other (please specify)………………………………………. 
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SECTION C: SOCIAL AND ENVIRONMENTAL ASPECTS        
 




1. Marital status: (please circle)   
  
1.  Married      
 
2.  Divorced   
 
3.  Single  
 
4.  Living together  
 
5.  Widowed  
 
2. How many people live in this house? 
 
1.   Males older than 15 years   
 
2.   Women (including yourself) older than 15 years  
 
3.   Children aged 15 years or younger  
 
 
3. What is your highest educational qualification?    
 
  ………………….. ................................  
  
4.  Do you have permanent job:  (please circle)   
  
1.  YES   
  
2.  NO  
     









5. For how many years have you held your current job?  
 
  ………………………………………….  
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6. What does your husband/partner do at work?        
…………………...................................  
  …………………………………………  
  …………………………………………  
7. Where does he work?  
 …………………………………………..  
  …………………………………………….  
  
8. What is the highest education qualification of your husband/partner?   
  ………………….. ................................     
  




10. How many people, living with you, have permanent jobs?   
……….……………………………………. 
 
11. Does anyone living in the house, work from home? (please circle)   
 
1.  Yes 
 
2.  No 
 
3.  Don’t know  
 
If yes, what do they do?  
  
 ............................................…………………………………………….  
 ………………………………………………………………………….  
  
  12. If maintaining or repairing your home, do you or handyman use lead-containing 
materials  (paints, solders etc).? (please circle) 
    
1.  Yes    
  
2.  No  
    








14. Describe the hobbies of people living in the house (for instance car repairs, 
pottery, welding, etc).  
  
  ………………………………………………  
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  ………………………………………………  
  ………………………………………………  
  
15. What is your opinion on air quality in your area? (please circle)   
  
1.  Good   
  
2.  Bad   
  
3.  I don’t know  
  
16. Are there any sources of environmental pollution around your home? (please 
circle) 
  
1.  Yes  
  
2.  No  
  
3.  If yes specify source  ,………………………………………………  
  
 …………………………………………………………………….  
  
17. How far is your home from the nearest the highway?   ….  .Km  
  
18 Do you use pesticides for insect control (flies, bugs, cockroaches, mosquitoes, in 
your  home?) (please circle)  
  
1.  Yes  
  
2.  No  
  
19. If yes, are these pesticides used in: (please circle)  
  
1.  Kitchen  
  
2.  Living room  
  
3.  Bedroom 
 
4.  Others, please specify 
………………………………………………  
  




21. How often do you use the pesticides?    
 
1.  In a week   
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2.  In a month  
 
22. Where do you store these pesticides? ……………………………………………  
 
23. Do you grow your own food? (vegetables, fruits, others) (please circle) 
 
1.  Yes  
  
2.  No   
  
If yes specify……………………………………  
  
24. Do you use pesticides in you garden? (please circle) 
  
1.  Yes  
    
2.  No  
  
If yes please specify which pesticide? 
………………………………………………….  
  
25. Do you or a member of your household fish?  (please circle) 
  
1.  Yes    
  
2.  No   
  
Where do you fish? Please name the location …………………………………….  
  
Please name the fish type  ……………………………………………………   
 




2.  No  
 
27. Is your house sprayed regularly by Malaria Control Programme  
 
  1. Yes…………………… 
 
  2. No 
   
If yes how often………………. 







SECTION D: INFORMATION ABOUT YOUR JOB  
 
Please list in chronological order all the jobs you were engaged in for the period of more 
than 6 months, over the past 10 years. Also mention whether you were exposed to any 




AND WHERE  
FROM   TO  DO YOU KNOW OF ANY CHEMICALS 
























      
 
Chemicals check list (please circle Y/N) 
  
1   Solvents (turpentine, spirits, paraffin,  Yes   No  
2   Paints        Yes   No 
3   Metals (in foundry, mine    Yes   No  
4   Cleaning fluids (floor, windows   Yes   No  
5   Polish (for floor, car polish    Yes   No  
6   Paint removers     Yes   No  
7  Oils/lubricants (grease….)    Yes   No  
8   Spray paints      Yes   No  
9   Spray oils      Yes   No  
10   Others, please specify     Yes   No  
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SECTION E: HEALTH          
In this section some information about your health status is requested.  
  
1.  Are you well at present?  
  
1.  Yes      
 
2.  No      
 
3.  Don’t know     
 
2.  If you are not well, what are the problems?  
  
 …..........................................…………………………………………  
  
 …..........................................…………………………………………  
         
3.  Do you suffer from any of the following? (circle correct answers please)       
 
 1.  Diabetes    
  
  Since when / How long …………………………………..   
  
    Are you on medication for this condition?  YES    NO  
  
  
 2.  Thyroid gland    
  
  Since when / How long  …………………………………..  
  
  Are you on medication for this condition?  YES    NO  
  
  
  3.  Liver disease  
  
  Since when / How long    
  
  Are you on medication for this condition?  YES    NO  
  
  4.  Heart disease    
  
  Since when / How long  
  
Are you on medication for this condition?   YES    NO  
 
5.  High blood pressure  
    
Since when / How long   
   Are you on medication for this condition?   YES    NO  
6.  Infectious/parasite disease, if yes please tick:   
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1. TB (tuberculosis)  
  
2. Pneumonia  
  
3. Virus hepatitis  
 
If other please specify ……………………..  
  
7.  Cancer     YES       NO  
  
If yes, please specify ……………………………………….  
  
If yes, did you receive treatment: ……………………………………..  
 
Please specify type of treatment……………………………………….    
  
 
8.  Are there any hereditary diseases in family (for example high blood 
pressure, lung  disease, etc.? )  
  
If yes, please specify …………………………..  
  
  
9.  Do you suffer from any other illnesses (for example skin condition etc):  
  
1.  Yes  
  
2.  No  
 
If yes, please specify)…............................... 
 
10.  Have you ever been given any home remedies for illnesses or to improve 
your health  (please circle)?   
  
1.  Yes  
 
If yes, please specify………………..     
  
2.  No    
 










11.  Are you taking any prescription medication at present? (please circle)  
  
1.  Yes:    
  
If yes, what medication are you taking, please specify:  
  
    …………………………………………………..  
  
   ……………………………………………………  
2.  No  
  
3.  Don’t know  
  
12.  Are you taking any special remedies during your pregnancy?  
 




 13.  How long did you breastfed your other children: 
 
  1. Child 1 (oldest)…………….. 
 
  2. Child 2………………………. 
 
  3. Child 3 ………………………. 
 
  4. Child 4……………………… 
 
  5. Child 5………………………. 
 
 
14.  Do you plan to breastfeed this child: 
 
 1. Yes 
 
 2. No 
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SECTION F: DIET AND LIFESTYLE  
 
Please answer questions about your usual diet before and during pregnancy:  
 
Table: Frequency of consumption of food / before / during pregnancy,  
1 =seldom;  2= at least once a week;  3-= almost every day  
  
 












(by respondent or in the 
area) Y/N 
PROTEINS 
Meat    
Poultry    
Processed meet (smoked 
sausage, ham etc) 
   
Tinned meat    
Eggs    
Fish fresh    
Fish tinned    
Fish smoked    
Sea food    
VEGETABLES AND FRUITS 
Vegetables root (potatoes, 
carrots, beetroot, onion etc) 
   
Vegetables leafy/ground 
(spinach, cabbage, lettuce, 
cucumbers, pumpkin, water 
melon etc) 
   
Vegetables vine/tree 
(mielie, beans, tomatoes, 
garlic) 
   
Fruits 
 
   
DAIRY PRODUCTS AND FATS 
Dairy products (milk)    
Butter and cheese    




   
Bread    
Sugar    
FLUIDS 
Fresh fruit juices    
Soft drinks    
Bottled water    
NON FOOD 
Non food items specify    
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2.  How many cups of coffee do you drink?  
  
1.  Daily  
  
2.  Weekly  
  
3.  How many cups of tea do you drink?  
  
1.  Daily  
  
2 . Weekly  
  
4.  How many bottles of beer do you drink?  
  
1.  Weekly  
  
2.  Monthly  
  
3.  None  
  
5.  How many bottles of wine do you drink?  
  
1.  Weekly  
  
2.  Monthly  
  
3.  None  
  
6.  How many glasses of vodka or other strong alcohols do you drink?  
  
1.  Weekly 
  
2.  Monthly  
  
3.  None  
  
7.  Do you smoke?   
  
1.  Yes  
  
2.  No  
  
8.  If yes, for how many years have you smoked regularly? ……years 
 
9.    At what age did you start to smoke regularly? …………. 
  
10.  What do you smoke? (please circle)     
  
cigarettes              self-rolled cigarettes   pipe    cigars  
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11.   How many cigarettes do you smoke daily?........... 
 
12.  If you do not smoke, did you smoke earlier?   Yes    No  
  
13.  At what age did you start to smoke regularly?........ 
  
14.   At what age did you quit smoking? …………. 
  
15. Within the last 6 months, did you take any drugs that influenced on your 
mood?  
  
1.  Yes  
  
2.  No   
 
3.  Refused to answer  
16. Do you have any hobby? 
  
1.  Yes  
 
2.  No  
 
3.  If yes, what?  
  
 







END OF QUESTIONNAIRE,  









МОРСКАЯ ПИЩА И ЗДОРОВЬЕ 
НАСЕЛЕНИЯ СЕВЕРА 
 
Вы согласны принять участие в исследовании? 
Да   Нет  
 
 




Дата   ׀ _ ׀ _ ׀ _ ׀ _ ׀ ׀ _ ׀ _ ׀ ׀ _ ׀ _ ׀ 
   день месяц  год 
 
 
Инициалы  ׀ _ ׀ _ ׀ _ ׀ 
  Ф   И   О  (Фамилия, Имя, Отчество) 
 
 













 мм рт. cт. 
 
 мм рт. cт. 
2  
 мм рт. cт. 
 
 мм рт. cт. 
Среднее  
 мм рт. cт. 
 















  , см 
Вес  
  , кг 
Окружность талии  
  , см 
Окружность бёдер  
  , см 
Индекс массы тела  









Время взятия крови  ׀ _ ׀ _ ׀ часов  
   
 
 
Взятие крови натощак Да   Нет  
 
 
Сколько времени прошло с последнего приёма 
пищи?  ׀ _ ׀ _ ׀ часов 
 
 
Что Вы кушали, пили в последний приём пищи? 
 
1          2   3   
 
4        5   6   
 
Употребляли ли Вы спиртные напитки вчера или 
сегодня? Да                              Нет  
Анкета 
 
Личные сведения, cоциальное положение 
 
Возраст  ׀ _ ׀ _ ׀ лет 
 
 
Дата рождения  ׀ _ ׀ _ ׀ _ ׀ _ ׀  ׀ _ ׀ _ ׀   ׀ _ ׀ _ ׀ 
день месяц год 
 
 
Пол Мужской  Женский  
 
 
Какое образование Вы получили? (Выберите только 
один вариант ответа) 
 
Обучение традиционным навыкам и знаниям вне школы   
Неоконченная начальная школа  
Начальная школа  
Неполная средняя школа 9 кл. (или 7-8 кл.)  
Полная средняя школа 11 кл. (или 10 кл.)  
Среднее профессиональное образование (техникум, 
училище, колледж)  
Неоконченное высшее образование (университет, институт), 
если 3 года и более  
Оконченное высшее образование (университет, институт)  
Аспирантура после университета, института (диплом 
кандидата, доктора наук)  
 
 
Какую работу Вы выполняете (выполняли) или по 
какой специальности Вы работаете (работали) 
большую часть Вашей жизни? 
 
должность       
место работы       
Я не работал(а)           Не знаю, нет ответа  
 
 
Какая у Вас была основная работа или способ 
заработать на жизнь последние 12 месяцев? 
 
должность       
место работы       
Я не работал(а)           Не знаю, нет ответа  
 
 
Вы сейчас? (Выберите да или нет в каждой строке) 
 
 Да Нет 
Работаете по найму полный рабочий день за плату   
Работаете по найму неполный рабочий день за плату   
Работаете не по найму, частный предприниматель   
Домохозяйка   
Неработающий пенсионер   
Учитесь   
Безработный(я)    
Не способны работать вследствие инвалидности, 
проблем со здоровьем 
  
В отпуске по беременности и уходу за ребёнком   
 
 
Сколько лет Вы живете в этой северной местности? 
 
 (лет (Если меньше, чем 12 месяцев, укажите 00 ׀ _ ׀ _ ׀
 
 
К какой этнической группе могла бы отнести себя Ваша 
мать? (Выберите только один вариант ответа) 
 
Аборигенные народы Севера («чистокровная» ненка или 








Смешанная группа (аборигенные и неаборигенные народы 
Севера) 
 
Не знаю, нет ответа  
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К какой этнической группе мог бы отнести себя Ваш 
отец? (Выберите только один вариант ответа) 
 
Аборигенные народы Севера («чистокровный» ненец или 








Смешанная группа (аборигенные и неаборигенные народы 
Севера) 
 
Не знаю, нет ответа  
 
 
В соответствии со свидетельством о рождении, 
паспортом, другими документами Вы относитесь к...? 
Русским     Украинцам     Белорусам      
 
Ненцам    Коми  
 
Другой национальности, пожалуйста, охарактеризуйте какой ↓ 
        
Не знаю, нет ответа  
 
 
По собственному мнению и ощущениям Вы относитесь 
к…? 
Русским     Украинцам     Белорусам      
 
Ненцам    Коми  
 
Другой национальности, пожалуйста, охарактеризуйте какой ↓ 
        
Не знаю, нет ответа  
 
 
Вы (выберите только один вариант ответа): 
 
Замужем/женат     Живете вместе   Разведен(а)  
Никогда не были замужем/женаты   Вдова/вдовец  
 
 
Сколько человек, включая Вас, в возрасте старше 18 
лет живут в Вашем доме?  
Число ׀ _ ׀ _ ׀ 
 
 
Сколько детей младше 18 лет живут в Вашем доме? 
Отметьте 00, если нисколько. 
Число ׀ _ ׀ _ ׀ 
 
 
Сколько человек в Вашей семье получают доход? 
Число ׀ _ ׀ _ ׀ 
 
 
Сколько составляет совокупный ежемесячный доход 
на каждого члена Вашей семьи в среднем, включая все 
источники: зарплаты, пенсии, пособия, стипендии, др.? 
Менее чем 1500   1500,1-2500  
2500,1-3500   3500,1-4500  
4500,1-6000   6000,1-8000  
8000,1-12000   Более чем 12000  
 
Не знаю, нет ответа   
Питание 
 
Являетесь ли Вы вегетарианцем (не употребляете мясо 
в пищу, но употребляете курицу и рыбу)? 
Да   Нет  
 
 
Соблюдаете ли Вы диету в настоящее время? 
 
Да       Нет    
 
Если да, какая это диета?  
        
Если да, как долго Вы соблюдаете диету? (Впишите 
количество  лет, месяцев): 
 месяцев ׀ _ ׀ _ ׀ лет ׀ _ ׀ _ ׀
Вы (отметьте ниже Да или Нет по каждому пункту): 
 
Страдаете сниженным аппетитом 
Да   Нет  
 
Страдаете повышенным аппетитом 
Да   Нет  
 
Страдаете хроническим желудочно-кишечным заболеванием 
Да   Нет  
 
Далее нам важно получить информацию о Ваших 
привычках в еде. При ответе на каждый вопрос отметьте, 
как часто Вы употребляли продукт, указанный в вопросе, за 
последние двенадцать месяцев. 
 
 
РЫБА И МОРЕПРОДУКТЫ / ТРАДИЦИОННАЯ ПИЩА 
 






















Рыба         
 
 
В период, когда Вы употребляли рыбу, как часто Вы 
ели нижеприведенные продукты? (Выберите по одному 
















треска, пикша, сайда 
      
Жареная треска,  
пикша, сайда       
Зубатка, камбала, 
морской окунь 
      
Лосось (сёмга), форель       
Скумбрия       
Сельдь       
Горбуша       
Cиг,  чир, пелядь, 
ряпушка, голец, омуль,  
нельма и др. подобная 
рыба 
      
Если Вы употребляли другую рыбу, впишите в пустые 











































Опишите, какую рыбу Вы едите чаще, начиная с 
наиболее часто потребляемой рыбы 1 и заканчивая 
наименее часто потребляемой 3. 
 
1 наиболее часто  
2  
3 наименее часто  
 
 3 
Зависит ли значительно Ваше потребление рыбы от 
сезона года? 




Если Да, укажите, преимущественно, какую рыбу в 
какое время года и как часто (выберите 1 в мес.; 2-3 в мес.; 
1 в нед.; 2 в нед.; 3+ в нед.) Вы употребляете. 
  
Сезон Виды потребляемой рыбы Как часто 
зима   
  
  
весна   
  
  
лето   
  
  





Если Вы ели рыбу, сколько составляла обычная 
порция? (1 порция =150 г) (Выберите по одному ответу 
в каждой строке) 
Вареная, припущенная рыба (порция)  
1  1.5  2  3+ 
 
Жареная рыба (порция) 
1  1.5  2  3+ 
 
 
Сколько раз в год Вы ели следующие продукты? 
(Выберите по одному ответу в каждой строке) 
 
 0 1-3 4-6 7-9 10+ 
Молоки      
Печень рыбы      
 
 
Как часто Вы употребляли консервы печень трески? 
_________ раз в месяц.  Отметьте 0, если  реже. 
 
 
Как часто Вы ели морских ракообразных (креветки, 
крабы)? (Выберите только один вариант ответа) 
никогда/редко       1 в мес.       2-3 в мес.       1+ в нед. 
 
 
Как часто Вы ели морских моллюсков (мидии, 
кальмары, морские гребешки)? (Выберите только один 
вариант ответа) 
никогда/редко       1 в мес.       2-3 в мес.       1+ в нед. 
 
 
По Вашим оценкам, достаточно ли рыбы Вы 
потребляли? 
Да   Нет  
 
 
Если Нет, почему Вы не потребляли больше рыбы? 
 
 Да Нет 
Слишком дорого   
Маленький выбор   
Трудно купить свежую рыбу   
Плохое качество   
Отсутствуют блюда быстрого приготовления   
Запах во время приготовления   
Трудно приготовить   
Не люблю вкус   
Члены семьи не любят рыбу   
Семейная привычка, мы не ели рыбу в моём детстве   
Пищевая аллергия   
Если другое важно, пожалуйста, укажите подробную информацию 
       
        
Как Вы считаете, изменилась ли доступность рыбы с 
1991 года? 
Меньше доступна      Больше доступна      Не изменилась 
 
Как часто Вы или члены Вашей семьи ловили рыбу? 
Еженедельно       
1-3 раза в месяц      
1-11 раз в год      
Никогда       
 
 
Какую часть от всех продуктов питания, потребляемых 
Вашей семьей, составляла рыба?  
 
Ничего/почти ничего  
Меньше половины   
Около половины   
Больше половины   
Почти всё   
Не знаю                                   
 
 
Какую часть от всей рыбы, потребляемой Вашей 
семьей, составляла заготовленная Вами рыба?  
 
Ничего/почти ничего  
Меньше половины   
Около половины   
Больше половины   
Почти всё   
Не знаю                                   
 
 
Как часто Вы ели следующие виды традиционной 
















Оленье мясо       
Олений жир       
Мясо диких 
животных  
      
Мясо тюленя        
Жир тюленя       
Мясо моржа       
Жир моржа       
Мясо кита       
Китовый жир       
Северные лесные 
ягоды 
      
Северные лесные 
грибы 




      
 
 
      
 
 
      
 
 
      
 
       
 
 
      
 
 
Вспомните, какая часть Вашего меню состояла из 
традиционных северных продуктов питания, включая 
рыбу? 
 
Ничего/почти ничего  
Меньше половины   
Около половины   
Больше половины   
Почти всё   




Из общего объема традиционной северной пищи, 
потребляемой в Вашей семье, какая часть была добыта 
членами Вашей семьи в последние 12 месяцев путем 
охоты, рыбалки, собирательства? 
 
Ничего/ почти ничего  
Меньше половины   
Около половины   
Больше половины   
Почти всё   




ДРУГИЕ ПРОДУКТЫ И ПРИГОТОВЛЕНИЕ ПИЩИ 
 
При ответе на каждый вопрос отметьте, как часто Вы 
употребляли продукт, указанный в вопросе, за последние 
двенадцать месяцев. 
 
Сколько стаканов каждого вида молока 
(кисломолочных продуктов) Вы пили? (Выберите по 




























      
Обезжиренное молоко 
0,5% 
      
 
 
Употребляли ли Вы сливки 10% и >? 
Да, практически ежедневно  Иногда  Нет  
 
 
Сколько чашек чая, каждого вида кофе Вы пили? 






















Чай        






       
 
 
Сколько стаканов пакетированных соков или 
газированных напитков, содержащих сахар, Вы пили? 






















      
 
 
Сколько примерно кусков или чайных ложек 
рафинированного сахара Вы обычно клали в напитки 
(чай, кофе и другие) в среднем в день? Отметьте 0, 
если Вы не используете сахар. 
 
_________ кусков или чайных ложек сахара в день 
 
 
Как часто Вы употребляли следующие продукты? 












ко раз в 
нед. 
1 раз 






       
Сметана        
Сливочное 
масло 
       
Маргарин        
Йогурт         
 
 
Как часто в среднем Вы употребляли злаки (сухие 
продукты из смеси зёрен), овсяные хлопья, мюсли? 
(Выберите только один вариант ответа)  
 
Никогда/редко 1-3 в нед. 4-6 в нед. 1 в день 
    
 
 
Сколько кусков хлебобулочных изделий и сухих 
хлебцев Вы употребляли (1/2 булочки = 1 кусок хлеба)? 














Ржаной (чёрный хлеб)       
Хлеб из муки грубого 
помола,цельнозерновой 
      
Пшеничный хлеб 
(белый хлеб, батон) 
      
Сухие хлебцы и т.д.       
 
 
Сколько бутербродов в среднем за неделю Вы 
употребляли со следующими рыбными продуктами? 
















Консервированная рыба       
Слабосолёная жирная 
рыба 
      
Икра       
 
 
Сколько бутербродов в среднем за неделю Вы 
употребляли с другими продуктами? (Выберите по 














Варенье, джем, мёд       
Твёрдый сыр 
жирностью 40-50% 
      
Обезжиренный 
твёрдый сыр  
      
Плавленый сыр       
Мясные продукты 
(колбаса, ветчина, 
бекон и др.), 
печеночный паштет 
      
 
 
Какой вид жира Вы обычно использовали с хлебом? 
(Выберите более чем один вариант, если необходимо) 
Я не использую жиры для бутербродов   
Сливочное масло      
Мягкий маргарин (напр., «Воймикс», «Рама»)   
Сало и другой жир домашних животных   
Другой вид жира (напишите какой): ___________________________ 
 
 
Если Вы использовали жир для бутербродов, каков 
слой данного продукта? (Выберите только один вариант 
ответа) 
Очень тонкий слой (3 г, меньше чайной ложки)   
Тонкий слой (5 г, 1 чайная ложка)    
Толстый слой (8 г, 1,5 чайной ложки)    
Очень толстый слой (12 г, больше 2 чайных ложек)  
 
 
Как часто Вы употребляли свиное сало? Отметьте 0, 
если Вы редко/никогда не едите сало. 
 
_________ раз в неделю 
 
 
Как часто Вы употребляли майонез? (Выберите только 










Майонез      
 
 
Как часто Вы употребляли рис, спагетти/макароны, 





1-3 в мес. 1  в нед. 2 в нед. 3+ в нед. 
Рис      
Макароны      
Бобовые      
 5 
Как часто Вы употребляли каши (рисовая, гречневая, 
пшённая, перловая, ячневая, манная, овсяная)? 














Каши       
 
Как часто Вы употребляли орехи, семечки? (Выберите 
















Орехи        
Семечки        
 
 
Как часто Вы употребляли фрукты: яблоки/груши, 
апельсины, бананы, виноград, персики и др.? 
















Фрукты        
 
 
Как часто Вы употребляли овощи, исключая 
















Овощи        
 
 
Как часто Вы употребляли картофель? (Выберите по 














Вареный картофель       
Жареный картофель       
 
Какой жир Вы обычно использовали при 
приготовлении пищи? (Вы можете выбрать более 
одного ответа) 
Подсолнечное масло     
Сливочное масло      
Твердый маргарин     
Мягкий маргарин      
Сливочное масло с добавками маргарина   
Соевое масло      
Оливковое масло      
Кукурузное масло      
Животный жир (свиное сало, говяжий, куриный и др.)   
 
Другой, напишите какой именно:      
Ничего       
 
Чем Вы обычно заправляли салаты? (Вы можете 
выбрать более одного ответа) 
Подсолнечное масло     
Майонез       
Сметана       
Оливковое масло      
Соевое масло      
Кукурузное масло      
 
Другое, напишите что именно    
Ничего       
 
 
Сколько яиц Вы обычно съедали за неделю (в 
жареном, вареном виде, в омлете)? (Выберите только 
один вариант ответа) 
 
0          1          2          3-4          5-6          7+ 
 
















      
Конфеты, шоколад       
Какие основные блюда Вы ели на обед, ужин. Укажите, 
как часто в среднем Вы употребляли то или иное 
блюдо за последние двенадцать месяцев. (Выберите 




























        
Переработанное 
мясо: сосиски и т.д. 
        
Консервированное 
мясо («Тушёнка») 




        
Курица, блюда из 
птицы 
        
Порция жирной рыбы 
(скумбрия, лосось и 
т.д.) 
        
Порция постной 
рыбы (треска и т.д.)  
        
Натуральный 
мясной, куриный 
бульон (суп на их 
основе) 
        
Уха, рыб. бульон         
Другое 
         
         
         
 
 
Как часто Вы ели солёные закуски, «фаст-фуд»? 














Картофельные чипсы       
Арахис       
Сушёную рыбу, 
кальмары 
      
«Фаст-фуд» (картошка 
фри, пицца, гамбургер) 
      
 
 
Как часто Вы употребляли мороженые 
полуфабрикаты? 
 
никогда/редко  1-3 в мес. 1 в нед. 
2-3 в нед.  4-6 в нед. 7+ в нед. 
 
 




Иногда, не каждый 
день 
Каждый день 
   
 
 
Как часто вы ели курицу вместе с кожей? 
Всегда        
Часто       
Иногда       
Никогда       
Я не ем курицу      
 
 
Добавляете ли Вы соль в уже приготовленную пищу? 
Нет, никогда  Да, обычно  Да, иногда  
 
 
Удаляете ли Вы видимый жир с мяса до его 
приготовления или перед употреблением в пищу? 
 
Да   Нет  
 
 





Принимаете ли Вы рыбий жир жидкий?  
Да ↓                              Нет  
Напишите 




















      
 ׀ _ ׀ _ ׀
лет 
 ׀ _ ׀ _ ׀
месяцев 
Принимаете ли Вы рыбий жир (омега-3 добавки) в капсулах? 
Да  ↓                          Нет  
Напишите 




















      
 ׀ _ ׀ _ ׀
лет 
 ׀ _ ׀ _ ׀
месяцев 
Принимаете ли Вы витамины/минералы? 
Да ↓                               Нет  
Напишите 
















      
 ׀ _ ׀ _ ׀
лет 
 ׀ _ ׀ _ ׀
месяцев 
2 
      
 ׀ _ ׀ _ ׀
лет 
 ׀ _ ׀ _ ׀
месяцев 
3 
      
 ׀ _ ׀ _ ׀
лет 
 ׀ _ ׀ _ ׀
месяцев 
Принимаете ли Вы другие пищевые добавки? 
Да ↓                              Нет   
Напишите 
















      
 ׀ _ ׀ _ ׀
лет 
 ׀ _ ׀ _ ׀
месяцев 
2 
      
 ׀ _ ׀ _ ׀
лет 
 ׀ _ ׀ _ ׀
месяцев 
3 
      
 ׀ _ ׀ _ ׀
лет 





Укажите, был(а) ли у кого-либо из Ваших близких 
родственников (родители, родные сёстры, братья) в 
возрасте до 60 лет: 
 
 Да Нет Не знаю 
Инфаркт миокарда или острый 
сердечный приступ  
   
Инсульт, кровоизлияние в мозг      
Гипертония    
Внезапная сердечная смерть    
 
 
Укажите, страдал ли кто-либо из Ваших близких 
родственников (родители, родные сёстры, братья) 
сахарным диабетом?  
Да   Нет   Не знаю  
 
 
Укажите, у кого-либо из Ваших близких родственников 
(родители, родные сёстры, братья) есть (были) 
 
проблемы с контролем избыточного веса?  
Да   Нет   Не знаю  
 
повышенный уровень холестерина? 




Есть ли у Вас какие-нибудь хронические заболевания 
или проблемы со здоровьем? 
Да  Нет   Не знаю, нет ответа  
 
 
Если «Да», укажите, пожалуйста, какие у Вас есть 
хронические заболевания или проблемы со здоровьем 
(в т.ч. гинекологические)? 
        
        
        
        
       
        
Есть ли у Вас какие-либо жалобы на состояние 
здоровья в настоящее время? 
Да   Нет  
 
 
Было ли у Вас острое респираторное заболевание 
(ОРЗ) или обострение хронического заболевания в 
течение последних 2-3 недель? 
Да  Нет   Не знаю, нет ответа  
 
 
В последний месяц (30 дней) были ли у Вас какие-либо 
из перечисленных ниже симптомов или жалоб? 
 
 Да Нет 
Боли в груди во время физической нагрузки    
Проблемы дыхания или кашель    
Боли в шее, плече    
Головные боли    
Отёки на ногах    
Приступы  головокружения   
Боли в суставах   
Боли в спине    
Проблемы пищеварения   
Высокая температура    
Болезни, выпадение зубов    
Болезни или раздражение кожи    
Нарушение зрения   
Нарушение слуха   




Когда-либо доктор, медицинская сестра или другой 
медицинский работник говорили Вам, что у Вас есть 
какие-либо из перечисленных ниже заболеваний? В 
каком возрасте Вам впервые об этом сказали? 
Получали ли Вы какое-либо лечение или принимали ли 
лекарства от этого состояния последние 12 месяцев?  
 
 
Высокое артериальное давление, гипертония 
Наличие заболевания: Да           Нет           Нет ответа  
В каком возрасте Вам впервые сказали?    Нет ответа  
Получали ли Вы какое-либо лечение или лекарства от этого 
состояния последние 12 месяцев? Да        Нет  
Было ли высоким артериальное давление во время беременности?  




Наличие заболевания: Да           Нет           Нет ответа  
В каком возрасте Вам впервые сказали?    Нет ответа  
Получали ли Вы какое-либо лечение или лекарства от этого 




Сердечный приступ, инфаркт миокарда 
Наличие заболевания: Да           Нет           Нет ответа  
В каком возрасте Вам впервые сказали?    Нет ответа  
Получали ли Вы какое-либо лечение или лекарства от этого 
состояния последние 12 месяцев? Да        Нет  
 
 
Флебит (воспаление вен/артерий) 
Наличие заболевания: Да           Нет           Нет ответа  
В каком возрасте Вам впервые сказали?    Нет ответа  
Получали ли Вы какое-либо лечение или лекарства от этого 
состояния последние 12 месяцев? Да        Нет  
 
 
Тромбоз верхних или нижних конечностей 
Наличие заболевания: Да           Нет           Нет ответа  
В каком возрасте Вам впервые сказали?    Нет ответа  
Получали ли Вы какое-либо лечение или лекарства от этого 




Наличие заболевания: Да           Нет           Нет ответа  
В каком возрасте Вам впервые сказали?    Нет ответа  
Получали ли Вы какое-либо лечение или лекарства от этого 
состояния последние 12 месяцев? Да        Нет  
 
 
Стенокардия, ишемическая болезнь сердца 
Наличие заболевания: Да           Нет           Нет ответа  
В каком возрасте Вам впервые сказали?    Нет ответа  
Получали ли Вы какое-либо лечение или лекарства от этого 




Наличие заболевания: Да           Нет           Нет ответа  
В каком возрасте Вам впервые сказали?    Нет ответа  
Получали ли Вы какое-либо лечение или лекарства от этого 
состояния последние 12 месяцев? Да        Нет  
 
 
Мигрень, частая головная боль 
Наличие заболевания: Да           Нет           Нет ответа  
В каком возрасте Вам впервые сказали?    Нет ответа  
Получали ли Вы какое-либо лечение или лекарства от этого 




Наличие заболевания: Да           Нет           Нет ответа  
В каком возрасте Вам впервые сказали?    Нет ответа  
Получали ли Вы какое-либо лечение или лекарства от этого 
состояния последние 12 месяцев? Да        Нет  
 
 
Другие аллергические заболевания 
Наличие заболевания: Да           Нет           Нет ответа  
В каком возрасте Вам впервые сказали?    Нет ответа  
Получали ли Вы какое-либо лечение или лекарства от этого 
состояния последние 12 месяцев? Да        Нет  
Если Да, какие       
 
 
Рак. Тип?        
Наличие заболевания: Да           Нет           Нет ответа  
В каком возрасте Вам впервые сказали?    Нет ответа  
Получали ли Вы какое-либо лечение или лекарства от этого 
состояния последние 12 месяцев? Да        Нет  
 
 
Диабет. Тип?        
Наличие заболевания: Да           Нет           Нет ответа  
В каком возрасте Вам впервые сказали?    Нет ответа  
Получали ли Вы какое-либо лечение или лекарства от этого 
состояния последние 12 месяцев? Да        Нет  
Был ли сахар высоким во время беременности?  
Да  Нет Сахар на верхней границе нормы (пре-диабет)  
 
 
Заболевания желчного пузыря (камни в желчном пузыре, 
застой желчи, воспаление желчного пузыря) 
Наличие заболевания: Да           Нет           Нет ответа  
В каком возрасте Вам впервые сказали?    Нет ответа  
Получали ли Вы какое-либо лечение или лекарства от этого 
состояния последние 12 месяцев? Да        Нет  
 
Болезни печени (гепатит, цирроз, печёночная 
недостаточность) 
Наличие заболевания: Да           Нет           Нет ответа  
В каком возрасте Вам впервые сказали?    Нет ответа  
Получали ли Вы какое-либо лечение или лекарства от этого 
состояния последние 12 месяцев? Да        Нет  
 
 
Заболевания почек (гломерулонефрит, пиелонефрит, 
мочекаменная болезнь, почечная недостаточность) 
Наличие заболевания: Да           Нет           Нет ответа  
В каком возрасте Вам впервые сказали?    Нет ответа  
Получали ли Вы какое-либо лечение или лекарства от этого 
состояния последние 12 месяцев? Да        Нет  
 
 
Заболевания щитовидной железы 
Наличие заболевания: Да           Нет           Нет ответа  
В каком возрасте Вам впервые сказали?    Нет ответа  
Получали ли Вы какое-либо лечение или лекарства от этого 
состояния последние 12 месяцев? Да        Нет  
 
 
Хроническая тревога, хроническая депрессия 
Наличие заболевания: Да           Нет           Нет ответа  
В каком возрасте Вам впервые сказали?    Нет ответа  
Получали ли Вы какое-либо лечение или лекарства от этого 
состояния последние 12 месяцев? Да        Нет  
 
 
Была ли у Вас аллергия на определенные виды 
продуктов? 
Да   Нет   
 
Если Да, отметьте на какие: 
Молоко и т.д.    
Цитрусовые (апельсины и т.д.)  
Рыба     
Ракообразные    
Другие (какие)        
 
 
Как бы Вы сказали о своём здоровье, что оно? 
Отличное    
Очень хорошее    
Хорошее     
Удовлетворительное   
Плохое     




Говорил ли Вам врач или медицинская сестра, что у 
Вас избыточный вес, ожирение? 
Да           Нет           Нет ответа  
В каком возрасте Вам впервые сказали?    Нет ответа  
Получали ли Вы какое-либо лечение или лекарства от этого 
состояния последние 12 месяцев? Да        Нет  
 
 
Говорил ли Вам врач или медицинская сестра, что у 
Вас высокий уровень холестерина? 
Да   Нет   Не знаю  
 
 
Когда Вам делали анализ крови на холестерин 
последний раз? 
В течение предыдущего года  
1-5 лет назад    
Более чем 5 лет назад   
Никогда     
Не знаю     
 
Последний раз Ваш холестерин был   
 
   
Давали ли Вам медицинские работники рекомендации 
изменить Ваше питание из-за здоровья? 




В каком возрасте у Вас была первая менструация? 
 
В ׀ _ ׀ _ ׀ лет 
 
 
Через какой период Ваш менструальный цикл стал 
регулярным? 
Через 1 год или менее  Более, чем через год  
До сих пор нерегулярный  Не помню   
 
 
До сих пор ли Ваш менструальный цикл регулярный? 
Да   Нет менструаций  
Мой менструальный цикл нерегулярный  
 
Если нет: 
Закончился ли по физиологической причине?   
Были ли удалены фаллопиевы трубы (придатки)?  
Была ли удалена матка (гистерэктомия)?   
Закончился ли менструальный цикл по другой причине?  
 
Вы беременны? 
Да   Нет  
 
 
В каком возрасте у Вас полностью прекратились 
менструации? 
 
В ׀ _ ׀ _ ׀ лет 
 
 
Как долго у Вас нет менструаций (с последней 
менструации)? 
Меньше, чем 1 год  
1-5 лет    
5-10 лет    
Больше, чем 10 лет  
 
Беременности, роды, грудное 
вскармливание 
 
Укажите год рождения и количество месяцев грудного 
вскармливания каждого ребенка (пожалуйста, сообщите о 
мертворожденных детях или умерших после родов). Если у 
Вас нет, и не было детей, переходите к следующему 
вопросу. 
 
Ребёнок Год рождения Количество месяцев 
грудного вскармливания 
1   
2   
3   
4   
5   
6   
7   










Употребляли ли Вы когда-либо контрацептивные 
таблетки? 
Да   Нет   
 
 
Если Да, как долго Вы употребляли контрацептивные 
таблетки? 
 лет ׀ _ ׀ _ ׀
 
 
В каком возрасте Вы начали употреблять 
контрацептивные таблетки? 
В ׀   лет ׀ _ ׀ _
 
 
Употребляете ли Вы сейчас контрацептивные 
таблетки?  
Да   Нет   
 
Если Да, напишите название препарата    
 
 
Употребление гормональных препаратов 









Употребляли ли Вы когда-либо гормональные 
таблетки/пластыри? 
Да   Нет   
 
 
Если Да, как долго Вы употребляли гормональные 
таблетки/пластыри? 
 лет ׀ _ ׀ _ ׀
 
 
В каком возрасте Вы начали употреблять 
гормональные таблетки/пластыри? 
В ׀   лет ׀ _ ׀ _
 
 
Употребляете ли Вы сейчас таблетки/пластыри?  
Да   Нет   
 








Употребляли ли Вы когда-либо гормональные 
крема/суппозитории? 
Да   Нет   
 
 
Если Да, как долго Вы употребляли гормональные 
крема/суппозитории? 
 лет ׀ _ ׀ _ ׀
 
 
В каком возрасте Вы начали употреблять 
гормональные крема/суппозитории? 
В ׀   лет ׀ _ ׀ _
 
 
Употребляете ли Вы сейчас крема/суппозитории?  
Да   Нет   
 




Препараты для сердечно-сосудистой системы 
 
 
Принимали ли Вы препараты регулярно? 
 
 Да Нет 
От высокого давления?   
От стенокардии?   





Если Вы ответили Да на один или более 
вышеуказанных вопросов, пожалуйста, укажите, какие 
препараты для сердечно-сосудистой системы Вы 
используете и когда начали лечение. 
 
Препарат   Начало лечения 
Год / Месяц 
1        
2        
3        
4        
5        
Принимаете ли Вы регулярно таблетки, содержащие 
ацетилсалициловую кислоту (аспирин) для 
профилактики сердечных заболеваний?  
Да   Сейчас нет, но принимал(а) раньше   
Нет, никогда не принимал(а)  
 
Если Да, укажите название      
Как долго Вы употребляете их  месяцев  лет 
 
 
Принимаете ли Вы регулярно препараты, понижающие 
уровень холестерина?  
Да   Сейчас нет, но принимал(а) раньше   
Нет, никогда не принимал(а)  
 
Если Да, укажите название      
Как долго Вы употребляете их  месяцев  лет 
 
 
Принимали ли Вы какие-либо препараты на протяжении 
последних двух недель? 
Да   Нет  
 
Если Да, это были лекарства: (выберите Да/Нет по 
каждому пункту) 
 
Лекарства Да Нет 
От высокого давления   
Другие сердечные препараты   
Для снижения холестерина   
От диабета:  Таблетки 
  Инсулин 
  
  
От боли    
От астмы   
От симптомов аллергии    
От хронического бронхита или эмфиземы   
От депрессии   
От нарушений пищеварения   
Oт бессонницы   
Успокоительные   
От простуды, гриппа, болей в горле   
Противовоспалительные гормоны (такие как 
преднизолон) 
  
Витамины/минералы   
Другие: 
     





Телосложение в начальной школе. (Выберите только 
один вариант ответа) 
Очень худощавая/ый  Худощавая/ый  Нормальная/ый  
 
Полная/ый  Очень полная/ый  
 
 
Телосложение в возрасте 18 лет. (Выберите только 
один вариант ответа) 
Очень худощавая/ый  Худощавая/ый  Нормальная/ый  
 
Полная/ый  Очень полная/ый  
 
 
Пытаетесь ли Вы изменить Ваш вес? 
Нет 





Пожалуйста, укажите уровень Вашей физической активности по 
шкале от самого низкого до самого высокого уровня в возрасте от 
14 до 30 лет, а также на сегодняшний день. Ниже представлена 
шкала от 1 до 10. Под физической активностью мы понимаем 
физическую нагрузку на улице и дома, а также 
тренировки/физические упражнения и другие виды физической 
активности, напр., прогулки и т.д. Обведите число, наиболее точно 
характеризующее уровень Вашей физической активности. 
 
Возраст Очень низкий   Очень высокий 
14 лет 1 2 3 4 5 6 7 8 9 10 
30 лет 1 2 3 4 5 6 7 8 9 10 
Сейчас 1 2 3 4 5 6 7 8 9 10 
 
 
Тренировались ли Вы / делали ли физические 
упражнения для здоровья (не менее 30 минут) 
регулярно последние 12 месяцев? 
Да   Нет   
 
 
Если Да, то: 
 
сколько месяцев   месяцев 
 
 




Сколько минут или часов в день в среднем Вы ходите / 
гуляете на открытом воздухе, в том числе до места 
Вашей работы и обратно? 
 








Зима      
Весна      
Лето      
Осень      
 
 
Какова степень физической нагрузки на Вашей работе? 
 
В основном сижу. Во время работы я хожу мало. Пример: 
офисная работа за столом.  
В основном хожу. Я хожу много, но мне не приходится 
поднимать и переносить тяжести. Пример: продавец, 
офисная работа, требующая много ходьбы. 
 
Поднимаю и переношу небольшие тяжести. На работе 
мне приходится много ходить и носить тяжести или часто 
подниматься по лестнице или в гору. Пример: почтальон, 
строитель. 
 
Занимаюсь тяжёлой физической работой. Физически моя 
работа очень тяжёлая, мне приходится поднимать и 
носить тяжести, копать. Пример: тяжёлая 
сельскохозяйственная работа или промышленная работа. 
 
Я не работаю  
 
 
В свободное от работы время как часто Вы выполняете 
физические упражнения, другую физическую нагрузку 
(работа по дому или на даче, быстрая ходьба) 
продолжительностью не менее 30 минут, такую, чтобы 
появилась небольшая одышка или выступил пот? 
 
Ежедневно  
4-6 раз в неделю  
2-3 раза в неделю  
Один раз в неделю  
2-3 раза в месяц  
Несколько раз в год и меньше  
Я не могу из-за болезни, инвалидности  
 
 
Какова степень Вашей физической активности в 
свободное от работы время? Если это зависит от 
сезона, отметьте группу, которая отражает степень 
физической активности в среднем за год. (Выберите 
один вариант ответа) 
 
Я в основном читаю, смотрю телевизор и делаю то, что 
не требует физической активности (в основном, сидячий 
образ жизни в свободное время). 
 
Я хожу, катаюсь на велосипеде или двигаюсь другим 
образом не менее 4-х часов в неделю (это включает 
прогулки, лёгкую работу на огороде, ходьбу на работу и с 
работы). 
 
Физическая активность включает занятия спортом на 
любительском уровне для поддержания здоровья и 
физической формы, т.е. занятия бегом, лыжами, 
гимнастикой, плаванием, играми с мячом, выполнение 
достаточно тяжёлой работы на огороде или 
равнозначные этому виды деятельности не менее 4-х 
часов в неделю. 
 
В моё свободное время я занимаюсь спортом 
профессионально, регулярно, несколько дней в неделю, 
участвую в соревнованиях по бегу, играм с мячом и в 





Сколько обычно времени в будний день, в свободное 
от работы время, Вы проводите сидя (сидя за столом, 
в гостях у друзей, за чтением, в транспорте, смотрите 
телевизор, лёжа или сидя)? 
 




Употребляете ли Вы алкоголь? 
Да   Нет  
 
 
Если да, как часто и какое количество Вы в среднем 
выпивали за 12 месяцев? (Выберите по одному ответу 




















Лёгкое пиво (5%, 
бутылок 1/2 литра) 
       
Крепкое пиво (более 
5%, бутылок 1/2 литра) 
       
Столовое вино, 
шампанское (менее 
12%, бокалов 120 мл) 
       
Креплёное вино, 
наливки (16-20%, 
бокалов 80 мл) 
       
Крепкие спиртные 
напитки: водка, коньяк, 
самогон, в том числе в 
коктейлях (40%, рюмок 
40 мл) 
       
 
 
Сколько лет Вы употребляете алкоголь в таких 
количествах?   ׀ _ ׀ _ ׀ лет 
 
 
Вспомните, сколько бокалов, бутылок следующего 
алкоголя Вы выпили за последние 7 дней? Если Вы не 
пили, отметьте 0. (Выберите по одному ответу в каждой 
строке) 
 
Лёгкое пиво (крепостью менее 5%, бутылок 1/2 литра)  
Крепкое пиво (крепостью более 5%, бутылок 1/2 литра)  
Столовое вино, шампанское (крепостью менее 12%,бокалов 120 мл)  
Креплёное вино, наливки (крепостью 16-20%, бокалов 80 мл)  
Крепкие спиртные напитки: водка, коньяк, самогон, в том числе в 




Не возникает ли у Вас мысль о необходимости 
отказаться от употребления алкоголя?  
Да   Нет  
 
 
Не надоедает ли Вам критика окружающих по поводу 
Ваших выпивок?  
Да   Нет  
 
 
Не возникает ли у Вас переживаний или чувства вины в 
связи с Вашими выпивками? 
Да   Нет  
 
 
Не бывает ли так, что Вы по утрам в первую очередь 
принимаетесь за выпивку для успокоения нервов или 
устранения явлений похмелья? 






Проживаете (проживали) ли Вы с заядлым 
курильщиком 
в настоящее время?  Да   Нет  
 
в детстве?   Да   Нет  
 
 
Сколько часов в среднем в день Вы находитесь в 
накуренном помещении? 
Больше, чем 5 часов  1-5 часов  




Вы курите в настоящее время?  
 
Да, каждый день  
Да, иногда, не каждый день  
Нет, я никогда не курил(а) или я выкурил(а) не более 
100 сигарет (примерно 5 пачек) за свою жизнь 
 
Нет, я курил(а) в прошлом  
 
 
Что Вы курите (курили): сигареты, папиросы, трубку, 
самокрутки, сигары? (Обведите в круг) 
 
 
Укажите в графе «Возраст» количество выкуриваемых 
в среднем сигарет в день. 
 
Возраст Количество выкуриваемых сигарет в день 
0 1-4 5-9 10-14 15-19 20-24 25+ 
15-19        
20-29        
30-39        
40-49        
50-59        
60-69        
 
 
Сколько в целом лет Вы курите (курили) ежедневно? 
Если меньше, чем 12 месяцев, укажите 00. 
 Лет ׀ _ ׀ _ ׀
 
 
Сколько в среднем сигарет/папирос Вы курите (курили) 
ежедневно?  
Количество сигарет в день ׀ _ ׀ _ ׀  
 
 
В каком возрасте Вы начали курить ежедневно? 
Возраст ׀ _ ׀ _ ׀ 
 
 
Вопрос для тех респондентов, кто бросил курить. 
Когда Вы бросили курить? 
 лет назад ׀ _ ׀ _ ׀
Если последние 12 месяцев: 
Меньше чем 1 месяц назад  1-6 месяцев назад  
6-12 месяцев назад  
 
Психологическое здоровье, стресс 
 
Оцените уровень стресса за последний год? 
Высокий   Средний   Низкий  
 
 
Чувствовали ли Вы депрессию за последний год? 
 
Совсем нет  
Не больше, чем до этого  
Немного больше, чем до этого  
Намного больше, чем до этого  
Не знаю, нет ответа  
 
 
Чувствовали ли Вы напряжение, испытывали стресс 
или подвергались давлению за последний месяц (30 
дней)? 
 
Совсем нет  
Да – в некоторой степени, но не больше, чем люди 
обычно испытывают 
 
Да – больше, чем люди обычно испытывают  
Да – моя жизнь практически невыносима  




Пожалуйста, скажите, насколько Вы удовлетворены 
качеством Вашей жизни в целом? 
 
Очень доволен(а)  
Скорее доволен(а)  
Более или менее  
Скорее не доволен(а)  
Очень не доволен(а)  
Не знаю, нет ответа  
 
Медицинский работник      
 
Интервьюер       
 




       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       














Universitetet i Tromsø Romssa universitehta

Miljøgifter i svangerskapet og i aMMeperioden
Vi ber deg fylle ut spørreskjemaet så nøye som mulig.
Skjemaet skal leses optisk. Vennligst bruk blå eller sort penn. Du kan ikke bruke komma, forhøy 0,5 til 1. 
Bruk blokkbokstaver.
Dersom du får for liten plass på enkelte spørsmål, vennligst noter på siste side, eller ta i bruk et ekstra ark.
Venligst besvar skjema innen en uke etter oppstart i prosjektet. Sendes sammen med blodtrykkssjema 
til UiT i vedlagte returkonvolutt.
sosiale forHold
Dato for utfylling av spørreskjema: dag mnd år
Dato..........................................................................................
Hva er ditt postnummer?..........................................................
Hva er ditt fødselsår:......................................................................
Hvor mange års skolegang/utdanning har du i alt, 
ta.også.med.grunnskole.og.videregående?. Antall.år
Hvor mange personer er det i ditt hushold? Voksne Barn
Hvor høy er den samlede bruttoinntekten i ditt hushold?
c Under.50.000.kr c 60.000-750.000.kr
c 50.000-300.000.kr c 75.000-900.000.kr.
c 30.000-450.000.kr c Over.900.000.kr
c 45.000-600.000.kr
Hva er ditt yrke?
.........................................................................................................................................................................................
(Ikke skriv her ‡) 





(Ikke skriv her ‡) 
Hva er din arbeidssituasjon? (Sett.om.nødvendig.flere.kryss)
c Arbeider.heltid c Arbeidssøkende
c Arbeider.deltid. c Under.attføring
c Hjemmeværende c Uføretrygdet
c Under.utdanning
oppvekst
Hva var din bostedskommune da du ble født, og i hvilke 
kommuner i Norge har du bodd lengre enn ett år?












Hvilket hjemmespråk har/hadde du, dine foreldre og 
besteforeldre? (sett.ett.eller.flere.kryss)
Norsk Samisk Kvensk Annet Vet.ikke
Dersom.annet.
beskriv
Morfar........ c c c c c .....................................................
Mormor.... c c c c c .....................................................
Farfar.......... c c c c c .....................................................
Farmor...... c c c c c .....................................................
Far................. c c c c c .....................................................
Mor.............. c c c c c .....................................................
Jeg.selv.... c c c c c .....................................................
Hva er din, din fars og din mors etniske bakgrunn? 
(sett.ett.eller.flere.kryss)
Norsk Samisk Kvensk Annet Vet.ikke
Dersom.annet.
beskriv
Min.bakgrunn..... c c c c c ..............................................
Mors.bakgrunn. c c c c c ..............................................
Fars.bakgrunn.... c c c c c ..............................................
Er du sykemeldt? (Sett.ett.kryss.i.hver.kolonne)
c Nei Hvordan.er.du.sykemeldt?
c Delvis.sykemeldt c Sykemeldt.korttids
c Fullt.sykemeldt c Sykemeldt.langtids
Universitetet i Tromsø Romssa universitehta
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Hva regner du deg selv som? (sett.ett.eller.flere.kryss)
Norsk Samisk Kvensk Annet Dersom.annet.beskriv
c c c c ....................................................................................................
vekt 
Hvor mye veide du før svangerskapet? (I hele kg)....
Hva var din egen fødselsvekt som nyfødt baby?
 (Gram) ...Vet.ikke.c 
Har du noen gang hatt vekttap på 5 kg eller mer, i så fall hvor 
mange ganger?
c Ja c Nei Antall.ganger
røyk og alkoHol
Dersom du røyker daglig eller tidligere har røykt 
daglig, hvor mange år har du da røykt til sammen? Antall.år
Er du til daglig utsatt for passiv røyking?
c Ja c Nei Antall.timer.daglig.
Er du totalavholdskvinne?

















Lettøl/cider.(0,5 l)............................. c c c c c c c
Øl/rusbrus.(0,5 l)............................... c c c c c c c
Vin.(glass)................................................ c c c c c c c
Brennevin.(drink/shot)..................... c c c c c c c

















Lettøl/cider.(0,5 l)............................. c c c c c c c
Øl/rusbrus.(0,5 l)............................... c c c c c c c
Vin.(glass)................................................ c c c c c c c
Brennevin.(drink/shot)..................... c c c c c c c
Likør/Hetvin.(glass)......................... c c c c c c c
Svært.lite Svært.mye
Alder  2 3 4 5 6 7 8 9 0
4.år.......................... c c c c c c c c c c
Før.svangerskapet...... c c c c c c c c c c





Ammet din mor deg da du var baby?
c Ja c Nei
Dersom.JA,.hvor.mange.måneder.til.sammen.fikk.du.morsmelk?
Totalt.antall.mnd..med.morsmelk ...Vet.ikke.c 
Oppfatter du din helse som:





tran, oMega-3 og fiskeolje
Bruker du flytende tran/omega-3/fiskeolje?











Om.vinteren......................................................................... c c c c c
Resten.av.året..................................................................... c c c c c
Var dette svangerskapet planlagt?
c Ja c Nei
Dersom.JA,.hvor.mange.måneder.tok.det.før.du.ble.gravid?
Antall.mnd..
Trengte du hjelp til å bli gravid i dette svangerskapet? 
(Behandlet.for.barnløshet;.hormonstimulering,.IVF,.mikroinjeksjon.ol.)
c Ja c Nei
Beskriv dine røykevaner før og i dette svangerskapet? 
(Sett.ett.kryss)
Ikke.røyker Av.og.til Daglig
6.mnd.før.svangerskapet......................... c c c
Ved.svangerskapets.start......................... c c c












Påvirker noen av følgende forhold kostholdet ditt? 
(Sett.om.nødvendig.flere.kryss)
c Er.vegetarianer/veganer c Har.anoreksi
c Spiser.ikke.norsk.kost.til.daglig c Har.bulimi
c Har.allergi/intoleranse c Prøver.å.gå.ned.i.vekt



















Helmelk.(søt, sur)............................................... c c c c c c
Lettmelk.(søt, sur).............................................. c c c c c c
Ekstra.lettmelk................................................... c c c c c c
Skummet.(søt, sur)............................................ c c c c c c
















Kokekaffe................................................ c c c c c c c
Traktekaffe.............................................. c c c c c c c
Pulverkaffe............................................ c c c c c c c
Presskanne.kaffe...................... c c c c c c c
Anne.kaffe.(latte, espresso ol.).... c c c c c c c
Svart.te...................................................... c c c c c c c
Grønn.te................................................... c c c c c c c
Bruker du følgende i kaffe eller te:
Kaffe Te
Sukker.(ikke kunstig søtstoff)................ c Ja c Nei c Ja c Nei
Melk.eller.fløte......................................... c Ja c Nei c Ja c Nei















Springvann/flaskevann.............. c c c c c c c














Appelsinjuice...................................................... c c c c c c
Annen.juice.......................................................... c c c c c c
Saft/brus.med.sukker.................................. c c c c c c
Saft/brus.sukkerfri......................................... c c c c c c
yogHUrt/kornBlanning
Hvor ofte spiser du yoghurt (1 beger)? (Sett.ett.kryss)
c Aldri/sjelden c 2-3.pr..uke
c .pr..uke c 4+.pr..uke
Hvor ofte spiser du kornblanding, havregryn eller müsli? 
(Sett.ett.kryss)
c Aldri/sjelden c 4-6.pr..uke
c -3.pr..uke c +.pr..dag
kosttilskUdd
Bruker du kosttilskudd?











......................................................................................................... c c c c c
......................................................................................................... c c c c c
......................................................................................................... c c c c c
......................................................................................................... c c c c c
Bruker du kapsler/piller med tran/omega-3/fiskeolje?











Om.vinteren......................................................................... c c c c c






Hvor mange skiver brød/rundstykker og knekkebrød/














Grovbrød................................................................. c c c c c c
Kneip/halvfint..................................................... c c c c c c
Fint.brød/baguett............................................ c c c c c c





Navn:.......................................................................................................................... c c c
Navn:.......................................................................................................................... c c c







Hva slags fett bruker du vanligvis på brødet?
c Bruker.ikke.fett.på.brødet
c Smør
c Hard.margarin.(f. eks. Per, Melange)
c Myk.margarin.(f. eks. Soft, Vita, Solsikke)
c Smørblandet.margarin.(f.eks. Bremyk)
c Brelett
c Lettmargarin.(f. eks. Soft light, Letta, Vita Lett)
c Middels.lett.margarin.(f. eks. Olivero, Omega)
Dersom du bruker fett på brødet, hvor tykt lag pleier du 
å smøre på? (En.kuvertpakke.med.margarin.veier.2.gram)..
(Sett.ett.kryss)
c Skrapet.(3.g). c Godt.dekket.(8.g)
c Tynt.lag.(5.g) c Tykt.lag.(2.g)
frUkt og grønnsaker















Epler/pærer........................................... c c c c c c c
Appelsiner.o.l.................................... c c c c c c c
Bananer.................................................... c c c c c c c
Annen.frukt........................................... c c c c c c c















Gulrøtter.................................................. c c c c c c c
Kål................................................................. c c c c c c c
Kålrot.......................................................... c c c c c c c
Brokkoli/blomkål............................. c c c c c c c
Blandet.salat........................................ c c c c c c c
Tomat......................................................... c c c c c c c
Grønnsakblanding.(frossen)..... c c c c c c c
Løk................................................................ c c c c c c c
Andre.grønnsaker........................... c c c c c c c
For de grønnsakene du spiser, kryss av for hvor mye du 
spiser hver gang: (Sett.ett.kryss.for.hver.sort):
Gulrøtter.(stk)..................................................... c ½ c  c .½. c 2+
Kål.(dl)...................................................................... c ½ c  c .½ c 2+
Kålrot.(dl)............................................................... c ½ c  c .½ c 2+
Brokkoli/blomkål.(buketter)..................... c -2 c 3-4 c 5+
Blandet.salat.(dl)............................................. c  c 2 c 3 c 4+
Tomat.(stk)............................................................ c ¼ c ½ c  c 2+
Grønnsakblanding.(frossen) (dl) .......... c ½ c  c 2 c 3+
ris, spagHetti, grøt, sUppe











Ris................................................................................................. c c c c c
Spaghetti,.makaroni,.nudler................................. c c c c c














Risengrynsgrøt................................................. c c c c c c
Annen.grøt.(havre o.l.).................................... c c c c c c












Som.hovedrett................................................................... c c c c c
Som.forrett,.lunsj.eller.kveldsmat................... c c c c c
fisk













Syltetøy.................................................................... c c c c c c
Brunost.helfet..................................................... c c c c c c
Brunost.halvfet/mager................................ c c c c c c
Hvitost.helfet....................................................... c c c c c c
Hvitost.halvfet/mager.................................. c c c c c c
Kjøttpålegg,.leverpostei............................ c c c c c c
Rekesalat,.italiensk.o.l.............................. c c c c c c
På hvor mange brødskiver pr. uke har du i gjennomsnitt 













Makrell.i.tomat,.røkt.makrell................ c c c c c c
Kaviar......................................................................... c c c c c c
Sild/ansjos/sardiner.................................... c c c c c c
Laks/ørret.(gravet/røkt).................................... c c c c c c
Svolværpostei/Lofotpostei..................... c c c c c c
Krabbepålegg..................................................... c c c c c c
Annet.fiskepålegg........................................... c c c c c c
Hvor mange poteter spiser du vanligvis (kokte, stekte, mos)?
(Sett.ett.kryss)
c Aldri/sjelden c .pr.dag c 4+.pr.dag
c -4.pr.uke c 2.pr.dag








hele.året vinter vår sommer høst
Torsk,.sei,.hyse,.lyr.................... c c c c c c
Steinbit,.flyndre,.uer................. c c c c c c
Laks,.ørret........................................... c c c c c c
Kveite...................................................... c c c c c c
Makrell................................................... c c c c c c
Sild............................................................ c c c c c c
Tunfisk.(ikke på boks)..................... c c c c c c
Ferskvannsfisk.(Abbor, 
gjedde, røye, sik, harr)....................... c c c c c c
Annen.fisk........................................... c c c c c c
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Dersom du spiser  fisk, hvor mye spiser du vanligvis pr. 
gang? (.skive/stykke.=.50.gram)
Kokt.fisk.(skive)................................................. c  c ,5 c 2 c 3+
Stekt.fisk.(stykke)............................................. c  c ,5 c 2 c 3+
Hvor mange ganger pr. år spiser du fiskeinnmat? 
(Sett.ett.kryss.for.hver.linje)
aldri -3 4-6 7-9 0-5 6+
Rogn........................................................................... c c c c c c
Fiskelever............................................................... c c c c c c
Dersom du spiser fiskelever, hvor mange spiseskjeer pleier 
du å spise hver gang? (Sett.ett.kryss)
c  c 2 c 3-4 c 5-6 c 7+












Fiskekaker/pudding/boller........................................................... c c c c c
Plukkfisk/fiskegrateng............................................................ c c c c c
Frityrfisk/fiskepinner............................................................... c c c c c
Andre.fiskeretter........................................................................... c c c c c
Hvor stor mengde pleier du vanligvis å spise av de ulike 
rettene? (Sett.ett.kryss.for.hver.linje)
Fiskekaker/pudding/boller.(stk.)  
(2 fiskeboller=1 fiskekake).................................... c  c 2 c 3 c 4+
Plukkfisk,.fiskegrateng.(dl)................... c -2 c 3-4 c 5+
Frityrfisk,.fiskepinner.(stk.).................... c -2 c 3-4 c 5-6 c 7+
I tillegg til informasjon om fiskeforbruk er det viktig å få 
kartlagt hvilket tilbehør som blir servert til fisk. 











Smeltet/fast.smør........................................................... c c c c c
Smeltet/fast.margarin/fett....................................... c c c c c
Seterrømme.(35%).......................................................... c c c c c
Lettrømme.(20%).............................................................. c c c c c
Saus.med.fett.(hvit/brun).............................................. c c c c c
Saus.uten.fett.(hvit/brun).............................................. c c c c c
For de ulike typene tilbehør du bruker til fisk, vær vennlig å 
kryss av for hvor mye du vanligvis pleier å spise. 
Smeltet/fast.smør.(ss)............... c ½ c  c 2 c 3 c 4+
Smeltet/fast.margarin.(ss)..... c ½ c  c 2 c 3 c 4+
Seterrømme.(ss)............................. c ½ c  c 2 c 3 c 4+
Lettrømme.(ss) c ½ c  c 2 c 3 c 4+
Saus.med.fett.(dl) c ¼ c ½ c ¾ c  c 2+
Saus.uten.fett.(dl) c ¼ c ½ c ¾ c  c 2+
kjøtt














Reinkjøtt.................................................................. c c c c c c
Andre.matvarer.fra.rein.(lever, nyre, 
margebein, hjerte, tunge, blod og annet)..... c c c c c c
Elgkjøtt,.andre.matvarer.fra.elg.......... c c c c c c
Rype,.annen.viltfugl..................................... c c c c c c












Steik.(okse, svin, får).......................................................... c c c c c
Koteletter................................................................................. c c c c c
Biff................................................................................................ c c c c c
Kjøttkaker,.karbonader............................................... c c c c c
Pølser........................................................................................ c c c c c
Gryterett,.lapskaus......................................................... c c c c c
Pizza.med.kjøtt.................................................................. c c c c c
Kylling....................................................................................... c c c c c
Bacon,.flesk......................................................................... c c c c c
Innmat.får/storfe.............................................................. c c c c c
Andre.kjøttretter............................................................... c c c c c
Hvor mange ganger i året spiser du hval-/selkjøtt? (Sett.ett.kryss)
aldri -3 4-6 7-9 0-5 6+
c c c c c c
Hvor mange ganger i året spiser du det brune kjøttet i 
krabbe (utenom krabbepålegg)? (Sett.ett.kryss)
aldri -3 4-6 7-9 0-5 6+
c c c c c c
Hvor mange ganger i året spiser du andre skalldyr (reker og 
skjell)? (Sett.ett.kryss)
aldri -3 4-6 7-9 0-5 6+
c c c c c c
Hvor mange måseegg eller egg fra annen sjøfugl spiser du i 
året? (Sett.ett.kryss)
aldri -3 4-6 7-9 0-5 6+
c c c c c c
Med tanke på de periodene av året der du spiser fisk, hvor 











Kokt.torsk,.sei,.hyse,.lyr........................................... c c c c c
Stekt.torsk,.sei,.hyse,.lyr......................................... c c c c c
Steinbit,.flyndre,.uer.................................................... c c c c c
Laks,.ørret.............................................................................. c c c c c
Kveite......................................................................................... c c c c c
Makrell...................................................................................... c c c c c
Sild............................................................................................... c c c c c
Tunfisk.(ikke på boks)........................................................ c c c c c
Ferskvannsfisk.(Abbor, gjedde, røye, sik, harr) ....... c c c c c
Annen.fisk.............................................................................. c c c c c
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Hvor mye bruker du vanligvis av disse sausene?
(Sett.ett.kryss.for.hver.linje)
Brun.saus.(dl)..................................... c ¼ c ½ c ¾ c  c 2+
Sjysaus.(dl)........................................... c ¼ c ½ c ¾ c  c 2+
Tomatsaus.(dl)................................... c ¼ c ½ c ¾ c  c 2+
Saus.med.fløte/rømme.(dl).... c ¼ c ½ c ¾ c  c 2+
Dersom du spiser følgende retter, oppgi mengden du 
vanligvis spiser:  (Sett.ett.kryss.for.hver.linje)
Steik.(skiver).......................................... c  c 2 c 3 c 4 c 5+
Koteletter(stk.)..................................... c ½ c  c .½ c 2+
Kjøttkaker,.karbonader.(stk)... c  c 2 c 3 c 4+
Pølser.(stk à 150g) ............................ c ½ c  c .½ c 2+
Gryterett,.lapskaus.(dl)............... c -2 c 3 c 4 c 5+
Pizza.m/kjøtt.(stykke à 100 g) ... c  c 2 c 3 c 4+











Brun.saus............................................................................... c c c c c
Sjysaus..................................................................................... c c c c c
Tomatsaus............................................................................. c c c c c
Saus.med.fløte/rømme.............................................. c c c c c
andre Matvarer
Hvor mange egg spiser du vanligvis i løpet av en uke
(stekte, kokte, eggerøre, omelett)? (Sett.ett.kryss)
c 0 c  c 2 c 3-4 c 5-6 c 7+













Om.sommeren................................................................... c c c c c
Resten.av.året..................................................................... c c c c c
Hvor mye is spiser du vanligvis pr. gang? (Sett.ett.kryss)
c .dl c 2.dl c 3.dl c 4+.dl
Hvor ofte spiser du bakevarer som boller, kaker,  













Gjærbakst.(boller ol.)....................................... c c c c c c
Wienerbrød,.kringle..................................... c c c c c c
Kaker........................................................................... c c c c c c
Pannekaker........................................................... c c c c c c
Vafler.......................................................................... c c c c c c
Småkaker,.kjeks................................................ c c c c c c
Lefser,.lomper.................................................... c c c c c c













Pudding.sjokolade/karamell................ c c c c c c
Riskrem,.fromasj............................................. c c c c c c
Kompott,.fruktgrøt,.hermetisk.frukt... c c c c c c
Jordbær.(friske, frosne)................................... c c c c c c
Andre.bær.(friske, frosne).............................. c c c c c c
Hvor ofte spiser/drikker du ville bær, inkludert syltetøy og 













Multebær................................................................ c c c c c c
Tyttebær................................................................... c c c c c c
Blåbær....................................................................... c c c c c c
Krøkebær................................................................ c c c c c c
Andre.bær.............................................................. c c c c c c













c c c c c c













Mørk.sjokolade................................................. c c c c c c
Lys.sjokolade...................................................... c c c c c c
Dersom du spiser sjokolade, hvor mye pleier du vanligvis å 
spise hver gang? Tenk.deg.størrelsen.på.en.Kvikk-Lunsj.sjokolade,.
og.oppgi.hvor.mye.du.spiser.i.forhold.til.den.
c ¼ c ½ c ¾ c  c .½ c 2+













Potetchips.............................................................. c c c c c c
Peanøtter................................................................. c c c c c c
Andre.nøtter......................................................... c c c c c c
Annen.snacks..................................................... c c c c c c
kostHold gjennoM Ulike livsfaser  
varM Mat


















Barndom................................................................. c c c c c c
Ungdom.3-9................................................. c c c c c c
Voksen.(før siste året)....................................... c c c c c c
Når du har spist fisk, hvor ofte har du da spist fet fisk (laks, 













Barndom................................................................. c c c c c c
Ungdom.3-9................................................. c c c c c c
Voksen.(før siste året)....................................... c c c c c c
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Barndom.vinter................................................................. c c c c c
Barndom.resten.av.året............................................. c c c c c
Ungdom.3-9.vinter................................................. c c c c c
Ungdom.3-9.resten.av.året............................. c c c c c
Voksen.vinter.(før siste året)....................................... c c c c c




Hva var barnefars fødselsvekt som nyfødt baby?
 (Gram) ...Vet.ikke.c 
Hva er barnefars høyde i dag? (cm)......... ...Vet.ikke.c
Hvilket hjemmespråk har/hadde barnefar, hans foreldre og 
hans besteforeldre? (sett.ett.eller.flere.kryss)
Norsk Samisk Kvensk Annet Vet.ikke
Dersom.annet.
beskriv
Morfar..... c c c c c .....................................................
Mormor.. c c c c c .....................................................
Farfar...... c c c c c .....................................................
Farmor.... c c c c c .....................................................
Far.......... c c c c c .....................................................
Mor......... c c c c c .....................................................
Barnefar... c c c c c .....................................................
Hva regner barnefar seg selv som? (sett.ett.eller.flere.kryss)
Norsk Samisk Kvensk Annet Vet.ikke Dersom.annet.beskriv
c c c c c ..............................................................................
Hva er barnefars, hans fars og hans mors etniske bakgrunn? 
(sett.ett.eller.flere.kryss)
Norsk Samisk Kvensk Annet Vet.ikke
Dersom.annet.
beskriv
Barnefars.bakgrunn.. c c c c c ......................................
Mors.bakgrunn.......... c c c c c ......................................
Fars.bakgrunn............. c c c c c ......................................
angÅende spørsMÅlene
Var noen av spørsmålene vanskelige eller nærgående? Hvis ja oppgi hvilke spørsmål og evt. kommentarer.































Hvor mange ganger i året har du spist hval-/selkjøtt? 
(Sett.ett.kryss.pr..linje)
aldri -3 4-6 7-9 0-5 6+
Barndom................................................................. c c c c c c
Ungdom.3-9................................................. c c c c c c
Voksen.(før siste året)....................................... c c c c c c
Hvor mange måseegg eller egg fra annen sjøfugl har du 
spist i året?.(Sett.ett.kryss.pr..linje)
aldri -3 4-6 7-9 0-5 6+
Barndom................................................................. c c c c c c
Ungdom.3-9................................................. c c c c c c
Voksen.(før siste året)....................................... c c c c c c
Hvor mange ganger i året har du spist det brune kjøttet i 
krabbe (utenom krabbepålegg)? (Sett.ett.kryss.pr..linje)
aldri -3 4-6 7-9 0-5 6+
Barndom................................................................. c c c c c c
Ungdom.3-9................................................. c c c c c c
Voksen.(før siste året)....................................... c c c c c c
Hvor mange ganger i året har du spist fiskelever?.
(Sett.ett.kryss.pr..linje)
aldri -3 4-6 7-9 0-5 6+
Barndom................................................................. c c c c c c
Ungdom.3-9................................................. c c c c c c
Voksen.(før siste året)....................................... c c c c c c
Når du har spist fisk, hvor ofte har du da spist ferskvannsfisk 













Barndom................................................................. c c c c c c
Ungdom.3-9................................................. c c c c c c
Voksen.(før siste året)....................................... c c c c c c
Hvor ofte har du spist fiskepålegg (Makrell, sild, ansjos, 
sardiner, røkt eller gravet laks/ørret, kaviar, fiskeleverpostei 














Barndom................................................. c c c c c c c
Ungdom.3-9................................. c c c c c c c
Voksen.(før siste året)....................... c c c c c c c
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Har du regelmessig menstruasjon fremdeles?
Ja                   Har uregelmessig menstruasjon
Vet ikke (menstruasjon uteblitt pga. sykdom o.l.) 
Bruk av hormonpreparat med østrogen
Nei
Hvis Nei;
har den stoppet av seg selv? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
operert vekk eggstokkene? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
operert vekk livmoren?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
annet?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Alder da menstruasjonen opphørte?
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KVINNER OG KREFT
Vi ber deg fylle ut spørreskjemaet så nøye som mulig.
Dersom du ikke ønsker å delta kan du unngå purring ved å sette kryss
for NEI og returnere skjemaet i vedlagte svarkonvolutt.
Skjemaet skal leses optisk. Vennligst bruk blå eller sort penn. 









med østrogen i overgangsalderen
Har du noen gang brukt østrogen-
tabletter/plaster? ..................................................................................
Hvis Ja; hvor mange år har du brukt 
østrogentabletter/plaster i alt? ............................................................................
Hvor gammel var du første gang du 
brukte østrogentabletter/plaster? ......................................................
Bruker du tabletter/plaster nå? ..........................
Ja NeiHar du noen gang vært gravid?
Hvis Ja; fyll ut for hvert barn du har født opplysninger om fød-
selsår og antall måneder du ammet (fylles også ut for dødfødte
eller for barn som er døde senere i livet). Dersom du ikke har født
barn fortsetter du ved neste spørsmål.
Menstruasjonsforhold
Hvor gammel var du da du fikk menstruasjon første
gang?
Hvor mange år tok det før menstruasjonen ble 
regelmessig?
Ett år eller mindre Mer enn ett år
Aldri Husker ikke
Ja Nei













Hvor høy er du?(i hele cm.) ..................................................................................
Hvor mye veide du da du var 18 år?(i hele kg.)
Hvor mye veier du i dag?(i hele kg.) ............................................
Høyde og vekt
Kroppstype i 1. klasse. (Sett ett kryss)
veldig tynn tynn normal tykk veldig tykk
Overgangsalder
Graviditeter, fødsler og amming
Hvor mange personer er det i ditt hushold?..........
Sosiale forhold
Er du: (Sett ett kryss)
gift samboer ugift skilt enke
Hvor høy er bruttoinntekten i husholdet pr. år?
under 150.000 kr. 151.000-300.000 kr.
301.000-450.000 kr. 451.000-600.000 kr.
601.000-750.000 kr. over 750.000 kr.
Hva er din arbeidssituasjon? (sett kryss)
Arbeider heltid Arbeider deltid Pensjonist
Hjemmearbeidende Under utdanning Uføretrygdet
Under attføring Arbeidssøkende
Yrke:
Hvor mange års skolegang/yrkesutdannelse har du 







Har du noen gang brukt 
hormonspiral (Levonova)? ............................................
Hvis Ja; hvor mange hele år har du brukt 
hormonspiral i alt? ........................................................................................................................
Hvor gammel var du første gang du fikk
innsatt hormonspiral?







Depresjon (oppsøkt lege) ..................................................





Har du eller har du hatt noen av følgende sykdommer?
Østrogenpreparat til lokal bruk i skjeden
Har du noen gang brukt østrogen-
krem/stikkpille? ......................................................................................
Hvis Ja;
bruker du krem/stikkpille nå? ..............................
Ja Nei
Ja Nei
UTFYLLENDE SPØRSMÅL TIL ALLE SOM  HAR BRUKT
ELLER BRUKER PREPARATER MED  ØSTROGEN I FORM
AV TABLETTER ELLER PLASTER.
Hvis du har svart «nei» på spørsmålene om hormonbruk i over-
gangsalderen, kan du gå videre til spørsmålene under «P-
pillebruk». Har du svart «ja», ber vi deg utdype dette nærmere
ved å svare på spørsmålene nedenfor. For hver periode med
sammenhengende bruk av samme hormonpreparat håper vi du
kan si oss hvor gammel du var da du startet, hvor lenge du bruk-
te det samme hormonpreparatet og navnet på dette. Dersom du
har hatt opphold eller skiftet merke skal du besvare spørsmålene
for en ny periode. Dersom du ikke husker navnet på hormonpre-
paratet, sett «usikker». For å hjelpe deg til å huske navnet på
hormonpreparatene ber vi deg bruke den vedlagte brosjyre som
viser bilder av hormonpreparater som har vært solgt i Norge.





Har du brukt p-piller eller  
minipiller?................................................................................................................
Hvis ja, hvor mange år
har du brukt p-piller i alt ....................................................
Bruker du p-piller nå? ..............................................................
For p-pillebruk ønsker vi å få vite navnet på p-pillen, årstallet
du startet å bruke den og hvor lenge du brukte dette merket
sammenhengende. Dersom du har hatt opphold eller skiftet
merke start på ny linje. For å hjelpe deg å huske navnet ber vi






Alder ved Brukt samme hormon- Navn på hormontablett/













Hvis Ja; hvor lenge har du brukt 
dette legemidlet sammenhengede?
Har du benyttet noen av disse 
legemidlene tidligere?
Hvis Ja; hvor lenge har du benyttet 












Alder ved Brukt samme p-piller P-piller
start sammenhengende (se brosjyre)




Angi nr. her dersom
du bruker to preparater
Angi nr. her dersom
du bruker to preparater
Angi nr. her dersom
du bruker to preparater
Antall sigaretter hver dag














Hvor mange søstre har du (ta med evt. døde)
Hvor mange døtre har du (ta med evt. døde)
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Røyker du daglig nå?
Røykte noen av dine foreldre da 
du var barn?
Hvis Ja, hvor mange sigaretter røykte de 
til sammen pr. dag?
Har du i løpet av livet røykt mer enn 
100 sigaretter til sammen? ..........................................Ja Nei
Røykevaner
Hvor gammel var du da du tok din 
første sigarett?
Hvis Ja, ber vi deg om å fylle ut for hver aldersgruppe 
i livet hvor mange sigaretter du i gjennomsnitt røykte 
pr. dag i den perioden.




Vi ber deg angi din fysiske aktivitet etter en skala fra
svært lite til svært mye. Skalaen nedenfor går fra 1-10.
Med fysisk aktivitet mener vi både arbeid i hjemmet og i
yrkeslivet, samt trening og annen fysisk aktivitet som tur-
gåing o.l. Sett kryss over det tallet som best angir ditt





















1 2 3 4 5 6 7 8 9 10
Mammografiundersøkelse
Har du vært til undersøkelse av brystene med 
mammografi ..........................................................................................
Hvis Ja;
hvor mange år er det siden du sist
var til mammografi? (hele år) ........................................................................................
Har du hatt noen form for
operasjon av bryst(ene)?
Godartet kul (angi alder for første gang) ..............................




Hvor mange timer pr. dag i gjennomsnitt går eller
spaserer du utendørs?
sjelden/ mindre 1/2-1 time 1-2 timer mer enn






Hvis Nei; hvor ofte og hvor mye drakk du i
gjennomsnitt siste året? (Sett ett kryss for hver linje)
Alkohol
Ja Nei
aldri/ 1 pr. 2-3 pr. 1 pr. 2-4 pr. 5-6 pr. 1 2+ 










Oppfatter du din egen helse som; (Sett ett kryss)
Meget god God Dårlig Meget dårlig
Hvor ofte bruker du følgende hudpleiemidler?





Hvor ofte har du solt deg i solarium?
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Hvor ofte dusjer eller bader du?
mer enn 1 g. 4-6 g. 2-3 g. 1 g. 2-3 g. sjel- 




Til slutt vil vi spørre deg om ditt 
samtykke til å kontakte deg på nytt pr. post.
Vi vil hente adressen fra det sentrale personregister.
Ja Nei
Takk for at du ville delta i undersøkelsen
Er du villig til å avgi en blodprøve?
Ja Nei
Hvor mange ganger pr. år er du blitt forbrent av solen
slik at du har fått svie og blemmer med avflassing
etterpå? (ett kryss for hver aldersgruppe)
Alder Aldri Høyst 2-3 g. 4-5 g. 6 eller






Hvor mange uker soler du deg pr. år i syden?







Hvor mange uker pr. år soler du deg i Norge eller
utenfor syden?







Når bruker du krem med solfaktor? (sett evt. flere kryss):
Hvilken solfaktor bruker du i disse periodene?
i påsken i Norge eller utenfor syden solferie i syden
aldri
påsken i Norge eller solferie i syden
utenfor syden
I dag ..................................................................................................................................
For 10 år siden ......................................................................................
Hvor mange uregelmessige føflekker større enn 5
mm har du sammenlagt på begge beina (fra tærne til
lysken)? Tre eksempler på føflekker større enn 
5 mm med uregelmessig form er vist i nedenfor.
0 1 2-3 4-6 7-12 13-24 25+
5 mm
aldri/ 1-3 1 2-4 5-6 1 2+ 
sjelden pr.mnd. pr.uke pr.uke pr.uke pr.dag pr.
dag
Solvaner
Får du fregner når du soler deg? ................
Hvilken øyefarge har du? (sett ett kryss)
brun grå, grønn eller blanding blå
Hva er din opprinnelige hårfarge? (sett ett kryss)
mørkbrun, svart brun blond, gul rød
Ja Nei
For å kunne studere effekten av soling på risiko for
hudkreft ber vi deg  gi opplysninger om hudfarge
Sett ett kryss på det tallet under fargen som best passer
din naturlige hudfarge (uten soling)
1 2 3 4 5 6 7 8 9 10
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